WO2021153674A1 - 薬剤フィーダ - Google Patents
薬剤フィーダ Download PDFInfo
- Publication number
- WO2021153674A1 WO2021153674A1 PCT/JP2021/003052 JP2021003052W WO2021153674A1 WO 2021153674 A1 WO2021153674 A1 WO 2021153674A1 JP 2021003052 W JP2021003052 W JP 2021003052W WO 2021153674 A1 WO2021153674 A1 WO 2021153674A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- rotating body
- outer rotating
- end surface
- annular upper
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 718
- 229940079593 drug Drugs 0.000 title claims abstract description 710
- 230000007246 mechanism Effects 0.000 claims abstract description 153
- 230000001105 regulatory effect Effects 0.000 claims abstract description 114
- 230000002093 peripheral effect Effects 0.000 claims abstract description 91
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims description 54
- 230000008844 regulatory mechanism Effects 0.000 claims description 48
- 238000001514 detection method Methods 0.000 claims description 40
- 230000033228 biological regulation Effects 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 230000000630 rising effect Effects 0.000 claims description 19
- 238000005096 rolling process Methods 0.000 claims description 19
- 230000001174 ascending effect Effects 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 8
- 238000013459 approach Methods 0.000 claims description 6
- 230000001276 controlling effect Effects 0.000 claims description 3
- 238000009751 slip forming Methods 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims 1
- 238000003860 storage Methods 0.000 description 28
- 230000005540 biological transmission Effects 0.000 description 14
- 230000033001 locomotion Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000035553 feeding performance Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000009512 pharmaceutical packaging Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241001146209 Curio rowleyanus Species 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G47/00—Article or material-handling devices associated with conveyors; Methods employing such devices
- B65G47/02—Devices for feeding articles or materials to conveyors
- B65G47/04—Devices for feeding articles or materials to conveyors for feeding articles
- B65G47/12—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles
- B65G47/14—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles arranging or orientating the articles by mechanical or pneumatic means during feeding
- B65G47/1407—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles arranging or orientating the articles by mechanical or pneumatic means during feeding the articles being fed from a container, e.g. a bowl
- B65G47/1414—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles arranging or orientating the articles by mechanical or pneumatic means during feeding the articles being fed from a container, e.g. a bowl by means of movement of at least the whole wall of the container
- B65G47/1428—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles arranging or orientating the articles by mechanical or pneumatic means during feeding the articles being fed from a container, e.g. a bowl by means of movement of at least the whole wall of the container rotating movement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0076—Medicament distribution means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/02—Pill counting devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G2201/00—Indexing codes relating to handling devices, e.g. conveyors, characterised by the type of product or load being conveyed or handled
- B65G2201/02—Articles
- B65G2201/027—Tablets, capsules, pills or the like
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07F—COIN-FREED OR LIKE APPARATUS
- G07F17/00—Coin-freed apparatus for hiring articles; Coin-freed facilities or services
- G07F17/0092—Coin-freed apparatus for hiring articles; Coin-freed facilities or services for assembling and dispensing of pharmaceutical articles
Definitions
- the present invention relates to a drug feeder that automatically supplies granular solid drugs such as tablets and ampoules in order to automate dispensing performed in hospitals, pharmacies, and the like. More specifically, the present invention relates to a drug feeder that randomly stores a large number of drugs having the same shape and aligns the drugs with a rotating body to sequentially deliver and discharge the drugs one by one. Is.
- the conventional drug feeder shown in Patent Document 1 Japanese Patent Laid-Open No. 2018-108277: US Pat. No. 10,828,238; WO 2018/128133
- the outer rotating body includes an internal space having an opening that opens upward and an annular upper end surface that surrounds the opening, and is rotatable about a virtual vertical line extending in the vertical direction in the internal space.
- the inner inclined rotating body is arranged in the internal space of the outer rotating body, and can rotate around a virtual inclined line inclined with respect to the vertical line in a state where a plurality of solid chemicals are placed on the upper surface portion.
- the regulation mechanism aligns a plurality of agents that have moved on the annular upper end surface of the outer rotating body along the rotation direction of the annular upper end surface when the outer rotating body is rotating.
- FIGS. 9 to 13 are a plan view and a vertical cross-sectional view of the configuration of the main part of the conventional drug feeder 10.
- 10 (A) is a plan view of the link mechanism 73 arranged at the uppermost portion of the drug feeder shown in FIG. 9 and the upper layer portion of the top plate 11A of the housing 11 removed, FIG. 10 (B). Is a plan view of the top plate 11A shown in FIG. 9B and the attachments 60, 71, and 72 on the top plate 11A removed.
- FIG. 11A is a front view, a right side view, and a right side view of the sorting mechanism 60.
- FIG. 11B is an exploded cross-sectional view of a main part of the conventional drug feeder.
- the top plate 11 and the like, the outer rotating body 20 and the inner inclined rotating body 30 show a vertical cross section, and the rotation drive mechanism 50 and the rotation transmission
- the members 42 and 43 are shown in appearance.
- the reference numerals and member names given in FIGS. 9 to 13 are the reference numerals given in Patent Document 1 (Japanese Patent Laid-Open No. 2018-108277: US Pat. No. 10,828,238; WO 2018/128133). Please note that some parts have different names. Further, in the following description, the description of the structure described in detail in Patent Document 1 will be omitted, and only the part related to the present invention will be described.
- the drug feeder 10 includes a top plate 11A having a through hole 11B located at the uppermost portion and having a circularly hollowed out central portion, and a housing 11 having the top plate 11A.
- a housing 11 having the top plate 11A.
- an outer rotating body 20 whose upper end is rotatably fitted in the through hole 11B is housed.
- the main body 21 of the outer rotating body 20 includes an internal space 22 having an opening 22A that opens upward, and an annular upper end surface 23 that surrounds the opening 22A.
- the outer rotating body 20 is rotatably supported in the housing 11 about a virtual vertical line CL1 extending in the vertical direction in the internal space 22.
- the inner inclined rotating body 30 is arranged in the internal space 22 of the outer rotating body 20, and in a state where a plurality of solid chemicals are placed on the upper surface portion, the inner inclined rotating body 30 is centered on a virtual inclined line CL2 inclined with respect to the vertical line CL1. It is rotatable and moves a plurality of agents on the annular upper end surface 23 of the outer rotating body 20 when rotating.
- This drug feeder includes a bearing mechanism 40 that rotatably supports both the inner inclined rotating body 30 and the outer outer rotating body 20, a rotation driving mechanism 50 that drives the rotation of the bearing mechanism 40, and a top plate of the housing 11. It includes a sorting mechanism 60 and a regulating mechanism 70 provided on the upper side of 11A.
- the bearing mechanism 40 keeps the outer rotating body 20 in a state where it can rotate about the vertical straight line CL1, and the inner inclined rotating body 30 in a state where it can rotate around the vertically inclined inclined line CL2. ..
- the rotating container (20, 30) of the double rotation type drug feeder is formed.
- the drug is lifted by the rotation of the inner inclined rotating body 30 and the drug is sorted by the sorting mechanism 60, so that the drug is fed from above the inclined portion 33 of the inner inclined rotating body 30 to the annular upper end surface of the outer rotating body 20. Carry on top of 23.
- the drug is horizontally transported by the rotation of the outer rotating body 20 and the drug is transported to the drop discharge port 14 while aligning the drug on the annular upper end surface 23 by the alignment function of the regulation mechanism 70.
- the upper surface of the annular inclined portion 33 located on the peripheral edge of the inner inclined rotating body 30 is processed into a loose serrated corrugation useful for scooping up the drug over one circumference (FIGS. 9 (A) and 10). reference).
- the inwardly inclined rotating body 30 is in a so-called outward downward state in which it is lowered toward the outside, that is, as it is farther from the center (see FIGS. 9B and 11B).
- this outer descent is a state in which the inner inclined rotating body 30 is installed in the outer rotating body 20 in an inclined manner, and the outer descent is performed at any part of the inclined portion 33, particularly at the highest rising position where the outer descent is the loosest. Since the outward downward inclination is maintained even at the portion above the annular upper end surface 23 of the body 20, the scooped drug is smoothly fed to the annular upper end surface 23 of the outer rotating body 20 by rolling by the inclined portion 33. Useful for.
- the bearing mechanism 40 (see FIGS. 9B and 11B) is composed of a plurality of members 41 to 43 dispersedly arranged in various places, such as a passive member 41 mainly composed of a radial bearing or the like. , And rotation transmission members 42, 43 made of a ring-shaped body or an annular body such as an O-ring made of hard rubber.
- the rotation drive mechanism 50 (see FIGS. 9B and 11B) has a rotation drive member 51 arranged under the rotation vessel (20 + 30) and a rotation drive motor 54 for axially rotating the rotation drive member 51. It is equipped with.
- the rotation transmission members 42 and 43 of the bearing mechanism 40 are also a part of the rotation drive mechanism 50.
- the rotation drive mechanism 50 rotates the rotation drive member 51 with the rotation drive motor 54 to rotate the outer rotating body 20 at a relatively high speed and the inner inclined rotating body 30 at a relatively low speed. ing.
- the sorting mechanism 60 (see FIGS. 9 to 11) is mainly composed of an elongated rod extending from the base end portion 61 of the swinging fulcrum to the tip end portion 62 of the swinging end.
- the base end portion 61 is supported above the top plate 11A and the outer rotating body 20 by the support portion 63, and the tip end portion 62 can swing up and down around the base end portion 61.
- Most of the chemicals carried on the inclined portion 33 without sliding down from the inclined portion 33 of the inner inclined rotating body 30 to the annular upper end surface 23 of the outer rotating body 20 are delivered to the tip portion 62 of the sorting mechanism 60. By abutting, it is returned to the recess 32 of the inner inclined rotating body 30.
- the first regulating mechanism 70 (see FIGS. 9 and 10A) is installed at a position ahead of the sorting mechanism 60 in the rotation direction of the outer rotating body 20 with reference to the rotation direction of the annular upper end surface 23 of the outer rotating body 20.
- the regulating member 71, the second regulating member 72 installed further ahead of the regulating member 71, the link mechanism 73 connected to the first regulating member 71 and the second regulating member 72, and a sample capable of accommodating the sample drug. It is equipped with a storage space 74.
- the swing center portion is located on the top plate 11A side, and the swing end portion is located on the annular upper end surface 23 of the outer rotating body 20.
- the regulation mechanism 70 narrows the width of the drug transport path on the annular upper end surface 23 from the outer peripheral side.
- a drop discharge port 14 that penetrates the top plate 11A up and down is formed, and the agent on the annular upper end surface 23 of the outer rotating body 20 is rotated there.
- the top plate 11A is also provided with a discharge guide 13 in order to feed the product.
- the drug carried on the annular upper end surface 23 of the outer rotating body 20 diagonally abuts on the side wall of the discharge guide 13 and then diagonally travels along the side wall to reach the drop discharge port 14. ing.
- a transport surface guide 12 that extends downward and further extends to be the most advanced is formed.
- a controller for controlling the operation of the rotary drive motor 54 and a power source for supplying operating power to them are also built in the housing 11 or provided outside the housing 11.
- a photo sensor or the like for detecting the fall of the drug at the drop discharge port 14 is also attached, and the detection signal is transmitted to the controller or the tablet counter.
- the rotation control of the controller starts from low-speed rotation, and after detecting the discharge of the first drug, further detects the discharge of a predetermined number of drugs, and then shifts to high-speed rotation.
- the remaining number is calculated from the total number of discharged substances specified in advance and the number of discharged items, and when the remaining number reaches the specified predetermined number, the rotation speed is reduced or an undesired excessive drop occurs after the chemical discharge is completed. It is also designed to rotate in the reverse direction to prevent it.
- the drug 5 may be referred to as a sample drug 5a, a randomly contained drug 5b, or an aligned drug 5c depending on the situation in which the drug 5 is placed.
- the work of regulating the drug transport route width and the random injection of the drug are completed.
- the person in charge of the work selects an appropriate one from a large number of agents 5 as the sample agent 5a, puts it in the sample storage 74, and then puts it in the sample storage area 74, and then puts it in one end of the link mechanism 73. It is carried out by a simple operation of adjusting the position of the link mechanism 73 so that the links come into contact with each other.
- both the first regulating member 71 and the second regulating member 72 move in conjunction with the link mechanism 73, and the outer rotating body is formed by the free ends of the first regulating member 71 and the second regulating member 72.
- the width of the drug transport path on the annular upper end surface 23 of 20 is narrowed in two places to the extent corresponding to the diameter of the sample drug 5a.
- the rotation drive member 51 rotates around the axis. This rotational motion is transmitted to the outer rotating body 20 by friction transmission via the first transmission member 42, and is also transmitted to the inner inclined rotating body 30 by friction transmission via the second transmission member 43. Therefore, the first transmission member 42 and the second transmission member 43 rotate in the same direction.
- the second transmission member 42 rotates at a higher speed than the second transmission member 43.
- the agent 5 on the inclined portion 33 of the inner inclined rotating body 30 among the randomly contained chemicals 5b accumulated in the inner bottom of the rotating container (20 + 30) is a serrated inclined portion. It is scooped up from a low position to a high position by the circulation motion of 33. As shown in FIG. 12B, the drug 5 carried to the point where the inclined portion 33 is higher than the annular upper end surface 23 of the outer rotating body 20 is mostly slipped or rolled based on the inclination of the inclined portion 33. Transfers onto the annular upper end surface 23.
- the agent 5 on the annular upper end surface 23 is to some extent depending on the difference in rotation speed when transferred from the inclined portion 33. It breaks apart. Some of them are arranged in a vertical line, such as when the drug 5 is small, and some of them are arranged in a vertical row or diagonally.
- the row of drugs 5 passes as it is, but the side-by-side drugs 5 are inside due to interference with the first regulating member 71.
- the drug 5 is pushed out from above the annular upper end surface 23, falls onto the inner inclined rotating body 30, and returns to the randomly contained drug 5b.
- the drug 5 that has passed through the first regulating member 71 is then carried to the second regulating member 72 by the rotation of the outer rotating body 20, and the same drug alignment is forced again.
- the aligned chemicals 5c that have cleared the double regulation and are aligned in a row in this way are placed one after another at the discharge guide 13 due to the circulating motion of the annular upper end surface 23 accompanying the rotation of the outer rotating body 20. It is brought into contact with the outer side surface of the discharge guide 13 which is obliquely intersected with the drug transport path on the annular upper end surface 23. Then, most of the aligned chemicals 5c immediately proceed along the contact side surface of the discharge guide 13 and are sent in a line to the drop discharge port 14.
- the separation distance of the drug 5 after that is widened so that the drug 5 is dropped by a photo sensor or the like installed in a place where the separation distance is sufficient. By detecting the drug 5, the drug 5 can be accurately counted.
- the drug is aligned by the regulation mechanism, so that it is no longer necessary to provide a fixed rectifying guide in the rotating body.
- the common range for drugs of various shapes and sizes is expanding. As the range of sharing has expanded, there has been an increase in demand for sharing not only differences in shape and size, but also drugs made of different materials.
- the rotation speed of the inner inclined rotating body can be reduced.
- the rotation speed of the inner inclined rotating body is lowered, the lifting speed of the medicine due to the rotation of the inner inclined rotating body is lowered, and the quantity of the medicine delivered from the inner inclined rotating body to the outer rotating body is reduced.
- the amount of chemicals on the inner bottom of the rotating container decreases, the distance and time required to lift the single-unit chemicals separated from the mass by the inner inclined rotating body becomes longer.
- the amount of drug that reaches the outer rotating body due to inertia is further reduced.
- the first and first widths of the drugs that can pass through the drug transport path are regulated.
- Two regulating members 71 and 72 of 2 are installed in a row in the front-rear direction, and a sorting mechanism 60 for regulating the height of the drug is placed in front of the regulating mechanism 70.
- the sorting member mechanism 60 has a tip that swings and escapes upward when the reaction force from the drug is strong in order to avoid damage to the drug, so that the height regulation is always reliable. It cannot be said that it will be done.
- the height regulation by the sorting mechanism 60 is a pretreatment for reducing the burden of the width regulation by the regulating mechanism 70, so that there is no fatal inconvenience in practical use.
- the common range is expanded as described above, not only the shape and size of the chemicals are different, but also the chemicals made of different materials, for example, not only the hard chemicals but also the brittle chemicals on the surface layer, and the shapes such as spheres and spindles that are easy to roll.
- such measures tend to weaken the height regulation function of the sorting members in the sorting mechanism, so that the height regulation function is required to be maintained.
- the sorting members for height regulation like the regulation mechanism for width regulation and then arrange them along the annular upper end surface of the outer rotating body. ..
- a large number of members are already arranged in a row around the annular upper end surface of the outer rotating body, and a new member is additionally inserted in the row to extend the length of the row. Is not preferable.
- An object of the present invention is to provide a drug feeder capable of efficiently delivering a drug even if the rotation of the inner inclined rotating body is reduced.
- Another object of the present invention is to provide a drug feeder that can efficiently deliver even a drug that is easy to roll by improving the outer rotating body.
- Another object of the present invention is to provide a drug feeder that can easily increase the drug storage capacity.
- Another object of the present invention is to provide a drug feeder in which undesired excess drug is less likely to be discharged.
- the drug feeder of the present invention includes an outer rotating body 200, an inner inclined rotating body 300, and a regulation mechanism 700.
- the outer rotating body 200 includes an internal space 220 having an opening 220A that opens upward and an annular upper end surface 230 that surrounds the opening 220A, and rotates about a virtual vertical line CL1 extending in the vertical direction in the internal space. It is possible.
- the inner inclined rotating body 300 is arranged in the internal space 220 of the outer rotating body 200, and in a state where a plurality of solid chemicals are placed on the upper surface portion, the inner inclined rotating body 300 is centered on a virtual inclined line CL2 inclined with respect to the vertical line CL1. It is rotatable and moves a plurality of agents on the annular upper end surface 230 of the outer rotating body when rotating.
- the regulation mechanism 700 aligns a plurality of agents that have moved on the annular upper end surface 230 of the outer rotating body along the rotation direction of the annular upper end surface when the outer rotating body is rotating.
- the drug feeder of the present invention in the peripheral region of the upper surface portion 320 of the inner inclined rotating body 300, there are a plurality of delivery portions (delivery portions) having an outward downward slope 341 (downward slope) that is lowered toward the outside even at the ascending position. ) 340 and a plurality of push-up ports 350 having no outward downward inclination 341 are alternately formed one by one in the circumferential direction.
- the plurality of delivery portions 340 transfer the chemicals onto the annular upper end surface 230 of the outer rotating body 200 by using the outward downward slope 341. It can be done. Further, the push-up portion 350 can push up one or more chemicals in the delivery portion 340 located in front of the inner inclined rotating body 300 in the forward rotation direction to the ascending position.
- the above vertical line is a virtual one, and the above-mentioned vertical line is typical, but it may be tilted from the vertical line as long as it does not impair the drug transfer function of the outer rotating body.
- a plurality of delivery portions 340 having an outward downward inclination 341 provided in a peripheral region of an upper surface portion of an inner inclined rotating body, and a plurality of push-up portions 350 having no outward downward inclination are provided. Since they are formed alternately one by one in the circumferential direction, a step is formed at the boundary between the delivery portion 340 and the push-up portion 350. That is, the push-up portion 350 is higher than the delivery portion 340. Therefore, when the delivery portion 340 in the peripheral region reaches the lowermost position with the rotation of the inner inclined rotating body, the drug is quickly placed on the delivery portion.
- the drug on the delivery portion 340 is pushed forward by the push-up portion 350 (particularly the stepped surface) behind the delivery portion 340 as the inner inclined rotating body 300 rotates.
- the drug can be pushed up onto the annular upper end surface 230 of the outer rotating body 200 with a high probability regardless of the amount of the drug and the slow rotation speed of the inner inclined rotating body. Therefore, according to the present invention, it is possible to realize a drug feeder capable of efficiently delivering a drug even if the rotation of the inwardly inclined rotating body is reduced.
- the ascending position is a position where the edge of the outward descending inclination 341 of the delivery portion 340 of the inner inclined rotating body coincides with the annular upper end surface 230 or is above the annular upper end surface 230. At this position, the drug on the outward downward slope 341 smoothly shifts to the annular upper end surface of the outer rotating body.
- the push-up portion 350 preferably includes a rising portion 350A formed continuously at the end of the delivery portion located in the reverse rotation direction of the inner inclined rotating body.
- the rising portion 350A serves as a stopper portion for easily rolling chemicals such as a spherical shape or a spindle shape, and exerts a function of pushing up these chemicals.
- the rising portion 350A has a rising surface that extends in the same direction as the virtual slope line CL2 that is continuous with the outward slope 341. This rising surface constitutes a reliable stopper portion.
- the plurality of delivery portions 340 include a first delivery portion 340A and a second delivery portion 340B that are alternately arranged in the circumferential direction of the peripheral region.
- the inner inclined rotating body 300 is continuous with the first convex portion 361 and the first convex portion 361 protruding from the first portion of the upper surface portion 320 adjacent to the peripheral edge region, and the outer peripheral edge of the upper surface portion. It has a convex portion 360 including a second convex portion 362 protruding from the second portion extending to.
- the first delivery portion 340A has a structure in which the upper surface portion 320 of the inner inclined rotating body and the descending inclined portion 340A are continuous.
- the second delivery portion 340B has a structure in which at least a part of the inclination 340A extends down to the outer surface of the first convex portion 361. It is preferable that the rising surface of the rising portion 350A extends to the outer surface of the second convex portion 362.
- the drug on the delivery portion 340 is likely to roll down to the upper surface portion 320 side adjacent to the peripheral region by its own weight. At that time, it is held down by these convex portions 361 and 362, so that the enhanced pushing-up ability can be maintained. Therefore, even a drug having a shape that easily rolls, such as a spherical shape or a spindle shape, can be pushed up to a height exceeding the annular upper end surface 230 of the outer rotating body with an accurate high probability.
- a frictional force is generated in the circumferential direction of the inner inclined rotating body in the portion of the upper surface portion 320 of the inner inclined rotating body 300 inside the peripheral region to promote stirring of a plurality of chemicals on the upper surface portion 320, and the first It is preferable that the accelerating means 321 for promoting the rolling of the drug in the direction toward the delivery portion 340A is provided.
- the promoting means 321 can be composed of a plurality of wavy irregularities that are aligned in the circumferential direction and extend toward the first delivery portion 340A.
- a small frictional force acts on the chemicals on the upper surface 320 of the inner inclined rotating body 300 from the inner inclined rotating body when the inner inclined rotating body is rotated. The drug is stirred accordingly.
- the promoting means 321 facilitates the loading of the drug into the first delivery portion 340A.
- the falling drug detecting means 560 that detects the falling of the drug discharged after alignment on the annular upper surface portion of the outer rotating body 200, and the falling interval of the drug are detected from the output of the falling drug detecting means, and the inside is determined according to the detection result.
- a controller 570 that controls the rotation of at least one of the inclined rotating body 300 and the outer rotating body 200 may be further provided.
- the controller 570 has a function of individually reversing the rotation directions of the inner inclined rotating body 300 and the outer rotating body 200, and the drug detected by the falling drug detecting means 560 while rotating the outer rotating body 200 in the forward direction. It is preferable to temporarily reverse the inner inclined rotating body in response to the drop detection.
- the inversion of the inner inclined rotating body 200 and the inversion of the outer rotating body 300 can be performed individually, and when the inner inclined rotating body 300 is reversed while rotating the outer rotating body in the normal direction, the drug is conveyed by the outer rotating body. It is possible to obtain a stirring effect that cannot be obtained only by the normal rotation of the inner inclined rotating body by reversing the inner inclined rotating body without slowing down the speed.
- the first convex portion 361 and the second convex portion 362 of the inner inclined rotating body 300 exert a large stirring effect at the time of reversal.
- the drug feeder is further provided with a discharge guide 13 provided behind the regulation mechanism 700 to guide the drug on the annular upper end surface 230 of the outer rotating body from the inner peripheral side to the outer peripheral side of the annular upper end surface and send it to the drop discharge port 14.
- a discharge guide 13 provided behind the regulation mechanism 700 to guide the drug on the annular upper end surface 230 of the outer rotating body from the inner peripheral side to the outer peripheral side of the annular upper end surface and send it to the drop discharge port 14.
- the outer rotating body 200 includes a plurality of grooves 231 arranged at predetermined intervals in the circumferential direction on the annular upper end surface 230, and these plurality of grooves extend in the radial direction and in the radial direction, respectively. It is preferable to have a widening part 231A with a widened width in the middle of.
- the plurality of grooves have a shape in which the width dimension becomes smaller toward the inner peripheral edge and the outer peripheral edge of the annular upper end surface 230 than the widening portion 231A.
- a desired roll suppression function can be easily exhibited without adding another member in or near the arrangement location of the sorting mechanism 600 or the regulating mechanism 700. Therefore, according to the present invention, it is possible to realize a drug feeder capable of efficiently delivering a drug that is easy to roll by improving the outer rotating body.
- the plurality of grooves 231 may reach the inner peripheral edge of the annular upper end surface 230.
- a bay-shaped recess 233 that becomes deeper as it approaches the inner peripheral edge is formed between two adjacent grooves 231 on the annular upper end surface 230 of the outer rotating body 200, and the recess 233 is formed inside.
- the opening On the peripheral side, the opening may be inward in the radial direction.
- the controller 570 reduces the rotation speed of the outer rotating body 200, and the falling drug detecting means 560 completes the discharge of the last drug.
- An annular inclined surface 232 is formed on the outer peripheral edge of the annular upper end surface 230 of the outer rotating body so as to decrease toward the outside in the radial direction over one circumference, and the plurality of grooves 231 extend to the inside of the annular inclined surface 232. It may be extended. In this way, when the drug on the outer rotating body 200 is urged in the outer peripheral direction by the discharge guide 13 or the like, as soon as the drug that has settled down at the groove 231 comes off the groove, the annular inclined surface 232 is tilted. Therefore, even if the rolling of the drug on the outer rotating body is suppressed, the drug is smoothly and quickly delivered from the outer rotating body in the outer peripheral direction.
- the virtual vertical line CL1 which is the center of rotation of the outer rotating body, is inclined by an angle ⁇ from the vertical line, and the inclined direction of the virtual vertical line CL1 is such that the portion of the outer rotating body near the drop discharge port 14 is raised. It is preferable that the angle ⁇ is smaller than the inclination angle ⁇ of the annular inclined surface 232.
- the inclination of the entire outer rotating body, and thus the inclination of the annular upper end surface 230 is smaller than the inclination of the inclined surface 232 of the outer peripheral portion of the annular upper end surface 230 of the outer rotating body (because the angle ⁇ is smaller than the inclination angle ⁇ of the inclined surface). ), The urging function of the inclined surface 232 is maintained without being impaired.
- a plurality of irregularities (234,235) in a scattered spot pattern may be formed between adjacent grooves 231.
- the chemicals are less likely to slip even when the outer rotating body is decelerated or reversely fed due to the action of the plurality of irregularities of the scattered spot pattern having high sliding resistance. There is. Therefore, the progressive feed rate of the outer rotating body can be increased. Therefore, according to this configuration, it is possible to realize a drug feeder that can efficiently deliver a drug that is easy to roll or a drug that is difficult to roll.
- annular inclined surface 232 that descends toward the outside in the radial direction is formed over one circumference, and is formed between two adjacent grooves 231.
- a plurality of irregularities (234, 235) are formed in the groove 231 between the recess 233 and the annular inclined surface 232.
- a plurality of irregularities (234, 235) may be formed in the entire area surrounded by the recess 233 and the annular inclined surface 232.
- a plurality of irregularities (234, 235) may be formed in the entire area surrounded by the groove 231, the recess 233, and the annular inclined surface 232. In this way, it is possible to improve the feeding performance of the drug which is hard to roll without impairing the feeding function of the drug which is easy to roll. In this way, it is possible to improve the feeding performance of the drug which is hard to roll without impairing the feeding function of the drug which is easy to roll.
- a sorting mechanism 600 may be further provided for aligning a plurality of solid chemicals carried on the annular upper end surface 230 of the outer rotating body 200 by the rotation of the inner inclined rotating body 300 when the outer rotating body rotates.
- the sorting mechanism 600 is configured to regulate the height of a plurality of agents on the annular upper end surface 230 of the outer rotating body 200.
- the regulating mechanism 700 may be configured to regulate the position in the lateral width direction and also regulate the height with respect to a plurality of agents on the annular upper end surface of the outer rotating body.
- the sorting unit mechanism 00 not only regulates the height of the chemicals, but also in addition to that, the rotating chemicals are arranged in a row.
- the regulation mechanism 700 whose original function is width regulation, also regulates height. As a result, it is possible to strengthen the height regulation at the time of aligning the medicines lined up on the annular upper end surface 230 of the outer rotating body.
- the regulation mechanism 700 narrows the width of the drug transport path on the annular upper end surface 230 of the outer rotating body from the outer peripheral side. Therefore, the regulation mechanism includes a height regulating portion 712 facing the annular upper end surface at a predetermined interval, and a width regulating portion 711 projecting over the annular upper end surface to regulate the width of the drug transport path.
- the height regulation unit 712 and the width regulation unit 711 are each composed of a step portion when the height regulation function is exerted on the regulation mechanism 700, both functions are performed by making the amount of protrusion to the inside of the step portion different. Is embodied.
- the regulation mechanism 700 is provided with a mechanism for variably adjusting the position of the width regulation unit 711 in order to variably adjust the width of the drug transport path according to the width dimension of the drug.
- a mechanism for variably adjusting the position of the width regulation unit 711 in order to variably adjust the width of the drug transport path according to the width dimension of the drug.
- the lid presses the sample drug and suppresses its lifting, it is possible to appropriately prevent the occurrence of an undesired situation such as the sample drug jumping out of the sample storage area.
- the lid of the sample storage area is made transparent, it is possible to easily visually confirm that the sample drug has been misplaced or removed.
- the sorting mechanism 600 may include one or more hanging objects 612 that hang down from above the annular upper end surface 230 of the outer rotating body 200 and can be deformed when the lower end portion is pushed sideways.
- the hanging object 612 regulates the height of the drug on the annular upper end surface 230.
- the hanging object 612 may be a loosely connected plurality of balls or spheres 613.
- a plurality of balls or spheres are loosely connected to form a chain, those having an appropriate weight and deformability are available on the market, so that a desired sorting mechanism can be easily realized.
- one or more hanging objects are composed of a plurality of hanging objects, and the plurality of hanging objects 612 have different radial positions of the outer rotating body. Further, it is preferable that the plurality of hanging objects 622 and 632 have different positions in the circumferential direction of the outer rotating body. If a plurality of hanging objects are distributed in the radial direction or the circumferential direction, even if the contact of the individual hanging objects with the drug is alleviated, the total of the hits of the multiple hanging objects with the drug is sufficient. Therefore, the required height regulation function can be exhibited.
- One or more hanging objects 622, 632 may include hanging objects hanging from the other end of the support member 621 having one end mounted on the radial outer side of the outer rotating body and extending over the regulation mechanism.
- the hanging object 632 may be located next to the regulating mechanism 700, and an attractive member 640 that exerts an attractive force on the hanging object 632 may be attached to the regulating mechanism. If the attracting member 640 is attached to the regulation mechanism so that the side-by-side hanging objects 632 are attracted toward the regulating member, the function of the side-by-side hanging objects can be easily strengthened and the shaking can be suppressed while avoiding the enlargement. It can be embodied.
- a plurality of hanging objects 622,632 may include objects of different sizes.
- the large-sized hanging object 622 can exert a relatively strong regulatory force but tends to hit the drug strongly, whereas the small-sized hanging object 633 can exert a relatively weak regulatory force but exerts a relatively weak regulatory force on the drug.
- the hit is weak. Therefore, if hanging objects of different sizes are provided, the magnitude of the regulating force and the action position are dispersed, so that the height regulation can be diversified.
- the hanging object 622 having a large ball or ball size preferably has a higher lower end position than the hanging object 632 having a small ball or ball size.
- the strength of the relationship between the droop and the drug changes according to the height of the lower end position of the droop.
- a manual adjustment mechanism 650 that can variably adjust the height regulated by the sorting mechanism 600 by manual operation, and a lower limit setting mechanism 651 that can mechanically set the lower limit of the adjustment range by sandwiching a drug or its substitute. You may. By placing the same sample drug 5a or substitute as the drug to be discharged sequentially in the lower limit setting mechanism and then imitating it, the basic lower limit of the adjustment range of the manual adjustment mechanism 650 is set easily and appropriately. be able to. When you want to raise the regulation height a little based on a trial run or actual run, you can easily make fine adjustments by operating the manual adjustment mechanism 650. Further, when it is desired to lower the regulation height further than the basic lower limit, it can be dealt with by operating the manual adjustment mechanism 650 after taking out the sample drug or the like from the lower limit setting mechanism 651.
- a scale member 652 indicating the height regulated by the sorting mechanism 600 adjusted by the manual adjustment mechanism 650 may be further provided. If the scale member 652 is provided, if the scale value is stored or recorded after the adjustment, the scale adjustment operation can be performed for the same drug without placing a sample drug or a substitute in the lower limit setting mechanism 651. It is possible to easily make adjustments.
- the internal space expansion body 800 includes a flange portion 810 provided with a through hole 811 corresponding to the opening 220A of the internal space 220 of the outer rotating body 200 and fixed to the upper end portion of the peripheral wall 11C of the housing 11, and the peripheral edge of the through hole 811. It is preferable to include a tubular portion 820 that stands up from the portion and extends above the flange portion so as to extend the internal space 220 upward. In this way, since the tubular portion stands above the through hole 811, the state is similar to that of the opening of the rotary container being extended upward, which is equivalent to the increase in the drug storage capacity of the rotary container. Become.
- the internal space expansion body 800 further includes a hanging portion 830 extending into the internal space 220 of the outer rotating body 200.
- the hanging portion 830 interferes with the regulation mechanism 700, the inner inclined rotating body 300, and the outer rotating body 200 in a state where the flange portion 810 is fixed to the top plate 11A located at the upper end of the peripheral wall 11C of the housing 11. It is located next to the regulatory mechanism 700 so as not to extend into the internal space 220. If such a hanging portion 830 is provided, the drug is tilted from the inside or the bottom of the tubular portion 820 of the internal space expansion body 800 toward the portion of the annular upper end surface 230 of the outer rotating body on which the regulation mechanism 700 acts. It is possible to prevent the occurrence of such an inconvenient situation.
- a falling drug detecting means 560 that detects the falling of the drugs discharged after alignment and a controller 570 that variably controls the rotation speed of the outer rotating body according to the detection of the falling drug detecting means 560 may be further provided.
- the controller 570 has a function of detecting the time length when one drug falls from the output of the falling drug detecting means 560 to estimate the drug size of the drug, and an outer rotating body according to the estimated value of the drug size. It has a function of changing the rotation speed of 200. If the controller 570 estimates the drug size according to the length of the detection time when the discharged drug is dropped, the dropped drug detecting means 560 is used not only for detecting the presence or absence of the dropped drug but also for measuring the size of the drug. As a result, undesired complications and cost increases such as adding a new detection member or replacing the detection member with a high-class product can be avoided.
- the controller 570 may be adapted to change the rotation speeds of the outer rotating body and the inner inclined rotating body from high speed to low speed at the time of initial operation before obtaining the estimated value.
- the size of the drug is completely unknown to the controller during the initial operation, such as when the drug is put into an empty rotating container and then operated for the first time. Because it was, it took a long time for the initial operation. However, if the speed is increased only in the first half of the initial operation, the time for the initial operation is shortened by that amount, so that the efficiency can be improved.
- the timing for switching the rotation speed from high speed to low speed for example, when the time required to lift the medicine from the bottom to the edge in the rotating container elapses, the medicine changes from the inner inclined rotating body to the outer rotating body. For example, when the time from delivery to the first action position of the regulatory mechanism has elapsed, or when these combination times have elapsed.
- the controller 570 may determine the height of the rotation speed according to the magnitude of the estimated value. Compared to a drop outlet with a constant size, a smaller drug with a noticeable difference in size is more likely to be dropped multiple times. Under such a situation where multiple drops occur, both rotating bodies are rotated at high speed when the estimated value of the drug size is large. However, when the estimated value of the drug size is small, both rotating bodies should be rotated at a low speed. By doing so, it is possible to easily and accurately prevent undesired multiple drops of the drug.
- the drug feeder may further include a rotation drive mechanism (541, 542) for rotating the inner inclined rotating body and the outer rotating body.
- a rotation drive mechanism a mechanism capable of individually reversing the rotation direction of the inner inclined rotating body 300 and the rotating direction of the outer rotating body 200 can be used in response to a command from the controller 570.
- the controller 570 has a function of temporarily reversing the outer rotating body when the outer rotating body is rotating in the normal direction and the falling drug detecting means 560 detects the falling drug. May be good. In this way, if the inversion of the inner inclined rotating body and the inversion of the outer rotating body can be performed individually, and then the inner inclined rotating body is temporarily reversed while rotating the outer rotating body in the normal direction when the drug is discharged. , The stirring effect of the drug can be obtained.
- a falling drug detecting means that detects the fall of the drug discharged after alignment, and a controller 570 that controls the rotation speed and the rotation direction of the outer rotating body according to the detection of the falling drug detecting means so as to discharge a predetermined number of drugs.
- the controller 570 decelerates the rotation speed of the outer rotating body 200 when the falling drug detecting means 560 detects the falling discharge of one drug immediately before the completion of the discharging, and the falling drug detecting means.
- the rotation of the outer rotating body 200 may be temporarily stopped or controlled to be temporarily rotated in the reverse direction. In this way, it is possible to easily and accurately prevent undesired multiple drops of the drug.
- FIG. 1A is a cross-sectional view taken along the line AA of the inwardly inclined rotating body of FIG. 1 (A). It is a front view of the inward inclined rotating body. It is a perspective view of the inward inclined rotating body.
- the structure of the outer rotating body of the drug feeder is shown, (A) is an overall vertical sectional view, (B) is an enlarged view of a part thereof, and (C) is an upper vertical sectional view. It is a top view of the annular upper end surface of the outer rotating body. It is an enlarged view of a part of an outer rotating body. It is a top view of the annular upper end surface of another outer rotating body.
- the structure of the regulatory mechanism of the drug feeder is shown, (A) is a plan view when a large sample drug is placed in the sample yard, and (B) is a plan view when a small sample drug is placed in the sample yard. (C) is a plan view, a front view and a bottom view of the first and second regulating members, and (D) and (E) are end view views, respectively.
- the structure of the sorting mechanism of the drug feeder is shown, (A) is a perspective view of the sorting mechanism and its installation destination portion, (B) is a front view of the first sorting member, and (C) is a front view of the second sorting member. be.
- the structure of the internal space expansion body of the drug feeder is shown, (A) is a perspective view, (B) is a bottom view, and (C) is a side view.
- the entire structure is shown on the drug feeder, (A) is a perspective view with the large lid open, and (B) is an external perspective view with the large lid closed.
- (A) shows the mechanical structure inside the drug feeder, and (B) is a block configuration diagram of the control unit.
- the overall structure of the conventional drug feeder is shown, (A) is a plan view, and (B) is a longitudinal front view.
- (A) is a plan view in which the link mechanism and the upper layer of the peripheral wall are removed, and (B) is a plan view in which the peripheral wall is also removed.
- (A) is a front view, a right side view, and a right side view of the sorting member
- (B) is a developed view of the main part of the feeder, and a vertical cross section of the peripheral wall and the rotating container is shown.
- the rotation drive mechanism and the rotation transmission member are illustrated in appearance.
- the operating state of the conventional drug feeder when the contained drugs are started to be aligned is shown, (A) is a plan view, and (B) is a longitudinal front view.
- an operating state in which the aligned drugs are sent to the drop discharge port is shown, (A) is a plan view, and (B) is a vertical sectional front view.
- FIGS. 1 to 8 are diagrams showing the configuration of the drug feeder 100 according to the embodiment of the present invention, and FIGS. 1 to 8 are substantially the same as the conventional drug feeder 10 shown in FIGS. 9 to 13.
- the same reference numerals as those given in FIGS. 1 to 13 are attached to the portions. Since the housing 11, the discharge guide 13, the drop discharge port 14, the bearing mechanism 40, and the overall arrangement of members are almost the same as those of the conventional drug feeder, repeated explanations are omitted.
- outer rotating body 20, the inner inclined rotating body 30, the rotation driving mechanism 50, the sorting mechanism 60, and the regulating mechanism 70 (see FIGS. 9 to 11) of the conventional drug feeder are each remodeled to perform new outer rotation. Since the body 200, the inwardly inclined rotating body 300, the rotation driving mechanism 500, the sorting mechanism 600, and the regulating mechanism 700, each part will be described in detail focusing on the points different from the conventional ones.
- the drug feeder 100 of the present embodiment includes an outer rotating body 200, an inner inclined rotating body 300, a sorting mechanism 600, and a regulating mechanism 700.
- the outer rotating body 200 includes an internal space 220 having an opening that opens upward and an annular upper end surface 230 that surrounds the opening 220A, and vertically in the internal space 220. It can rotate around the extending virtual vertical line CL1.
- the inner inclined rotating body 300 is arranged in the internal space 220 of the outer rotating body 200, and a plurality of solid chemicals are placed on the upper surface portion 320 with respect to the vertical line CL1. It can rotate around the inclined virtual inclination line CL2.
- the inner inclined rotating body 300 moves a plurality of chemicals on the annular upper end surface 230 of the outer rotating body 200 when rotating.
- the regulation mechanism 700 aligns a plurality of agents that have moved on the annular upper end surface 230 of the outer rotating body 200 along the rotation direction of the annular upper end surface 230 when the outer rotating body 200 is rotating.
- the sorting mechanism 600 is configured to regulate the height of a plurality of agents on the annular upper end surface 230 of the outer rotating body 200.
- the drug feeder of the present embodiment in the peripheral region of the upper surface portion 320 of the inner inclined rotating body 300, there are six places having an outward descending inclination 341 that is lowered toward the outside even in the ascending position.
- the delivery portion 340 and the six push-up portions 350 having no outward downward inclination 341 are alternately formed one by one in the circumferential direction.
- the ascending position is a position where the edge of the outward descending inclination 341 of the delivery portion 340 of the inner inclined rotating body 300 coincides with the annular upper end surface 230 or is above the annular upper end surface 230.
- each of the six delivery portions 340 transfers the drug onto the annular upper end surface 230 of the outer rotating body 200 by using the outward downward inclination if one or more chemicals are on the outward downward inclination 341 at the ascending position. It is for letting you. Further, the six push-up portions 350 can push up one or more chemicals in the delivery portion 340 located in front of the inner inclined rotating body 300 in the forward rotation direction to the ascending position.
- the inwardly inclined rotating body 300 shown in FIG. 1 is a modification of the above-mentioned inwardly inclined rotating body 30.
- 1 (A) to 1 (D) show the structure of the inwardly inclined rotating body 300 of the drug feeder 100.
- 1 (A) to 1 (D) are a plan view, a cross-sectional view, a front view, and a perspective view of the inner inclined rotating body 300.
- the inwardly inclined rotating body 300 is mainly composed of a disk-shaped main body 310, and is provided with a central protrusion 31 similar to the conventional one in the center of the upper surface.
- the upper surface portion 320 around the central protrusion 31 is substantially flat.
- the upper surface portion 320 may be recessed like the upper surface portion 32 of the inwardly inclined rotating body 30 of the conventional drug feeder, but in this example, the upper surface portion 320 is substantially flat in consideration of strength, processing, and the like.
- a frictional force is generated in the circumferential direction of the inner inclined rotating body 300 in the portion of the upper surface portion 320 of the inner inclined rotating body 300 inside the peripheral region to promote stirring of a plurality of chemicals on the upper surface portion 320, which will be described later.
- the accelerating means 321 for promoting the rolling of the drug in the direction toward the first delivery portion 340A is provided.
- the promoting means 321 is composed of three wavy uneven groups composed of a plurality of narrow and long linear grooves arranged in the circumferential direction and extending toward the first delivery portion 340A.
- a small frictional force acts on the chemicals on the upper surface portion 320 of the inner inclined rotating body 300 from the inner inclined rotating body 300 when the inner inclined rotating body 300 is rotated. , The drug is stirred accordingly.
- the promoting means 321 facilitates the loading of the drug into the delivery portion 340A.
- the push-up portion 350 includes a rising portion 350A continuously formed at the end portion of the delivery portion 34 located in the reverse rotation direction of the inner inclined rotating body 300.
- the rising portion 350A serves as a stopper portion for easily rolling chemicals such as a spherical shape or a spindle shape, and exerts a function of pushing up these chemicals.
- the rising portion 350A has a rising surface 350B that extends in the same direction as the virtual slope line CL2 that is continuous with the outward slope 341.
- the outward downward angle of the outward downward inclination 341 of each delivery portion 340 is approximately 45 °, which is larger than the external inclination angle ⁇ when the inner inclined rotating body 300 is mounted, which is approximately 20 ° to 30 °. Therefore, even if the inner inclined rotating body 300 is mounted in the outer rotating body 200 in an inclined state, the delivery portion 340 is located at an ascending position where the inclination of the delivery portion 340 is closest to the horizontal when rotating in that state. The outward downward angle with respect to the horizontal is maintained at about 15 ° or more.
- a corrugated uneven pattern similar to that of the promoting means 321 is also formed in such a delivery portion 340.
- the six delivery sections 340 are composed of a first delivery section 340A and a second delivery section 340B that are alternately arranged in the circumferential direction of the peripheral region.
- the inner inclined rotating body 300 is continuous with the first convex portion 361 and the first convex portion 361 protruding from the first portion of the upper surface portion 320 adjacent to the peripheral edge region, and the outer peripheral edge of the upper surface portion 320. It has three convex portions 360 including a second convex portion 362 protruding from the second portion extending to.
- the first delivery portion 340A has a structure in which the upper surface portion 320 of the inner inclined rotating body 300 and the descending inclined portion 341 are continuous.
- the second delivery portion 340B has a structure in which at least a part of the inclination 341 extends down to the outer surface of the first convex portion 361. Then, the rising surface 350B of the rising portion 350A extends to the outer surface of the second convex portion 362.
- the drug on the delivery portion 340 is likely to roll down to the upper surface portion 320 side adjacent to the peripheral region by its own weight. At that time, it is held down by these first and second convex portions 361 and 362, so that the enhanced pushing-up ability can be maintained. Therefore, even a drug having a shape that easily rolls, such as a spherical shape or a spindle shape, can be pushed up to a height exceeding the annular upper end surface 230 of the outer rotating body 200 with an accurate high probability.
- the convex portion 360 may be attached to all the delivery portions 340 and the push-up portion 350, but in this embodiment, it is attached only to the second delivery portion 340B.
- FIGS. 2 and 3 is a modification of the above-mentioned outer rotating body 20.
- 2 (A) to 2 (C) are for explaining the structure of the outer rotating body 200 of the drug feeder 100
- FIG. 2 (A) is a vertical sectional view of the outer rotating body 200
- FIG. 2 (B) is an enlarged vertical cross-sectional view of the upper right end portion of FIG. 2 (A)
- FIG. 2 (C) is a vertical cross-sectional view of the outer rotating body 200 in which the tilted state is specified.
- FIG. 3 (A) is a plan view relating to the annular upper end surface 230 of the outer rotating body 200
- FIG. 1 is a plan view relating to the annular upper end surface 230 of the outer rotating body 200
- 3 (B) is an enlarged view relating to a part of the annular upper end surface 230
- FIG. 3 (C) is another type
- 3 (D) is a plan view of the outer rotating body 200 related to the annular upper end surface 230
- FIG. 3D is an enlarged view of a part of the annular upper end surface 230 of the outer rotating body 200 of another type.
- the outer rotating body 200 (see FIG. 2 (A)) has a shape in which the upper portion 215 and the lower portion 210 are integrated and the bottom of the bowl-shaped main body is cut.
- the diameter of the internal space 220 of the outer rotating body 200 is maximum at the annular upper end surface 230 at the uppermost position, and the diameter becomes smaller as the diameter is lowered from the annular upper end surface 230. Therefore, the inner inclined rotating body 300 can be freely accommodated and removed from the internal space 220 of the outer rotating body 200, and it is easy to assemble and replace parts.
- the annular upper end surface 230 of the upper portion 215 (see FIG. 2B) has an inclined surface 232 formed on the outer peripheral side portion over one circumference.
- the inclination angle ⁇ of the inclined surface 232 is highlighted in FIG. 2B, but is, for example, about 7 °.
- the vertical line CL1 (two-dot chain line in the figure) corresponding to the rotation center axis of the upper 215 or the outer rotating body 200 is only an angle ⁇ from the vertical line (one-dot chain line in the figure) 201. It is tilted.
- this inclination angle ⁇ is highlighted in FIG. 2C, it is, for example, about 3.5 ° so as not to impair the drug transport function, and is smaller than the above-mentioned inclination angle ⁇ .
- the inclination of the inclined surface 232 from the horizontal is the maximum inclination ( ⁇ + ⁇ ) in the state of the left inclined surface 232 in the figure and the minimum inclination in the state of the right inclined surface 232 in the figure with the rotation of the annular upper end surface 230. It fluctuates with ( ⁇ - ⁇ ).
- the inclination angle ⁇ of the inclined surface 232 is larger than the inclination angle ⁇ of the outer rotating body 200, the outer peripheral portion of the inclined surface 232 is always maintained in a state of being lower than the horizontal.
- the direction of the inclination (angle ⁇ ) of the vertical line CL1 is not shown, but the height (vertical position) of the upper surface (drug transport path) of the annular upper end surface 230 of the outer rotating body 200 is the drop discharge port 14 (FIG. 8). ), It is going to be higher.
- the inclination (angle ⁇ ) may be individually embodied by mounting the outer rotating body 200 in the housing 11 of the drug feeder 10, but since the inclination ( ⁇ ) is small, for example, the housing 11 of the drug feeder 10 It is also possible to embody the upper surface of the shelf board or the like to which the above is attached by inclining it by an angle ⁇ .
- a plurality of grooves 231 are equidistantly pitched in the circumferential direction on the annular upper end surface 230 (drug transport path) of the outer rotating body 200. Is formed in large numbers. It is made.
- Each of these grooves 231 is formed by engraving a shape close to a rhombus or a spindle shape, the longitudinal direction is directed to the radial direction of the annular upper end surface 230, and the width is reduced at both ends in the radial direction. The width of the groove 231 is widened in the middle of the radial direction to form the widened portion 231A.
- the drug is easily settled.
- the depth e of the deepest portion of the groove 231 is deeper than the depth d of the inclined surface 232 described above.
- the chemical agent from the groove 231 to the inclined surface 232 The movement is smooth.
- a plurality of 33 are also formed on the inner peripheral portion of the upper surface of the annular upper end surface 230.
- Each of the engraved 233s is located between two adjacent grooves 231 and 231 and has a bay-like shape that is deeper toward the inner circumference. It is useful for quickly returning the easily rolling drug that has been attracted to the circumferential side from the drug transport path of the outer rotating body 200 onto the inner inner inclined rotating body 300.
- the recess 233 may be opened radially inward on the inner peripheral edge side.
- the inner surface of these plurality of grooves 231 and the inner surface of the inclined surface 232 and the concave portion 233 are smooth surfaces so as not to hinder the movement of the drug.
- the surface of the portion of the annular upper end surface 230 excluding the plurality of grooves 231 and the inclined surface 232 is blasted or the like in order to prevent the chemical from slipping too much. It has been roughened.
- 3 (C) and 3 (D) are structures for forming a rough surface other than blasting, unlike the examples of FIGS. 3 (A) and 3 (B).
- an annular inclined surface 232 that descends toward the outside in the radial direction is formed over one circumference, and between two adjacent grooves 231.
- a bay-shaped recess 233 is formed, which is formed and becomes deeper as it approaches the inner peripheral edge.
- a plurality of irregularities (234, 235) are formed in the entire area surrounded by the two grooves 231 and the recess 233 and the annular inclined surface 232.
- a plurality of scattered spots consisting of 235 dents on a bowl having a diameter of about 0.5 mm, which is sufficiently smaller than the diameter of the drug to be handled, are formed, and a convex portion (234) is formed by a flat portion around the dents. ..
- the plurality of dents 235 are formed at substantially equal intervals, and unlike the blasted surface, the dents 235 are partitioned by the flat surface portion 234, so that they are not in close contact with each other.
- the progressive feed rate of the outer rotating body 200 can be increased.
- the planar contour shape of the plurality of recesses 235 is arbitrary, and may be rectangular or other shapes. Further, the plurality of recesses 235 may be formed concentrically and radially.
- FIGS. 4 (A) to 4 (E) show diagrams for explaining the regulatory mechanism 700.
- FIG. 4A is a plan view of the regulation mechanism 700 when the large sample drug 5a is placed in the sample storage 740
- FIG. 4B is a plan view of the small sample drug 5a placed in the sample storage 740. It is a top view of the regulation mechanism 700 at the time.
- FIG. 4C is a drawing showing parts used for the first regulation member 710 and the second regulation member 720, the upper part is a plan view of this part, and the middle part is a front view of this part. The lower figure is the bottom view of this part.
- 4 (D) is an end view of the component as viewed from the direction of arrow E shown in FIG. 4 (C), and FIG.
- FIG. 4 (E) is a view from the direction of arrow F shown in FIG. 4 (C). It is an end view of this part.
- the regulation mechanism 700 is the same as the conventional regulation mechanism 70 shown in FIGS. 9 and 10, but the first regulation member 710, the second regulation member 720, and the sample storage 740 are improved.
- the first regulatory member 710 has the leftmost swing center portion located on the housing 11 side in FIGS. 4A and 4B. In FIGS. 4A and 4B, the rightmost swinging end is located above the annular upper end surface 230 of the outer rotating body 200.
- the first regulating member 710 and the second regulating member 720 exhibit a width regulating function of narrowing the drug transport path width on the annular upper end surface 230 from the outer peripheral side according to the advance / retreat of the link mechanism 73 in the longitudinal direction (FIG. FIG. 4 (See (A) and (B)).
- the first regulating member 710 is formed not only with a lower portion 711 as a width regulating portion having a width regulating function, but also with an upper portion 712 as a height regulating portion which was not found in the first regulating member 71 described above. ing. As shown in FIGS. 4 (D) and 4 (E), the upper portion 712 projects toward the inner peripheral side of the lower portion 711, and the upper portion 712 and the lower portion 711 have an inclined surface. Therefore, in the first regulating member 710, the lower portion 711 performs a strict width regulating function according to the state of the link mechanism 73, and the upper portion 712 performs a gentle height regulation.
- the second regulating member 720 is also the same as the first regulating member.
- the sample storage 740 is improved in the regulatory mechanism 700. Further, a spring 730 for urging the link mechanism 73 toward the sample storage 740 is attached.
- the lower portions 711 and 712 of the swinging ends of the first and second regulating members 710 and 720 are the width of the drug transport path on the annular upper end surface 230. Is narrowed down to the amount that one drug passes through.
- a small lid 741 and a set screw 742 are attached in the sample storage area 740.
- the small lid 741 is a lid that can be opened and closed and is made of a transparent member, it is useful for preventing forgetting to store or take out the sample drug 5a.
- the set screw 742 is for fixing the small lid 741 so that the closed small lid 741 is not opened by the urging force of the spring 730.
- the link mechanism 73 for copying is brought into contact with the sample drug stored in the sample storage 740 manually or by a spring force, and a pushing force is applied to the sample drug. Even when the lid 741 presses the sample drug, it suppresses its lifting. Therefore, it is possible to appropriately prevent the occurrence of an undesired situation such as the sample drug jumping out of the sample storage 740. Further, if the lid 741 of the sample storage 740 is made transparent, it is possible to easily visually confirm that the sample drug has been misplaced or removed.
- FIG. 5A and 5B show the structure of the sorting mechanism 600 of the drug feeder 100
- FIG. 5A is an external perspective view of the sorting mechanism 600 and its installation destination portion
- FIG. 5B is a sorting mechanism 600
- FIG. 5C is a front view of the first sorting member 610
- FIG. 5C is a front view of the second sorting member 620 of the sorting mechanism 600.
- the sorting mechanism 600 is arranged at a position aligned with the first sorting member 610 arranged upstream of the regulating mechanism 700 in the drug transporting path of the annular upper end surface 230 of the outer rotating body 200 and the regulating mechanism 700 in the drug transporting path. It is provided with a second sorting member 620 provided.
- the first sorting member 610 and the second sorting member 620 exert a sorting function in multiple stages.
- the first sorting member 610 and the second sorting member 620 are attached to the top plate 11A of the housing 11 that includes the discharge guide 13 and supports the regulation mechanism 700.
- the first sorting member 610 (see FIGS. 5A and 5B) is a support member 611 having a short length whose vertical position can be adjusted by a manual screw mechanism, and a support member attached to a portion near the tip thereof. It is equipped with two front-stage hanging objects 612 that move up and down along with 611.
- the front hanging object 612 (see FIG. 5 (B)) is a chain formed by loosely connecting a plurality of large balls 613 (two spheres in the figure), and it is easy if a commercially available ball chain or the like is sufficient. It can be realized at low cost.
- the second sorting member 620 (see FIGS. 5A and 5C) also has a long support member 621 whose vertical position can be manually adjusted, and a support member 621 attached to a portion near the tip thereof. It includes two middle-stage hanging objects 622 and two rear-stage hanging objects 632 that move up and down along with it, and a manual adjustment mechanism 650 that adjusts the vertical position of the support member 621.
- the middle ball 622 (see FIG. 5C) is a chain of a plurality of middle balls 623 (three spheres in the figure), but the middle ball 623 is smaller than the large ball 613. And the number of connections is increasing.
- the two rear hanging objects 632 are also made by loosely connecting a plurality of small balls 633 (seven in the front and six in the back in the figure) to form a chain, and the small balls 633 become smaller than the middle ball 623 and are connected. The number is increasing.
- the manual adjustment mechanism 650 manually raises the support member 621 to widen the gap between the support member 621 and the lower limit setting mechanism 651, and then places the sample drug 5a (the above-mentioned sample storage 740) on the lower limit setting mechanism 651.
- a scale member 652 is attached to the lower limit setting mechanism 651.
- the scale of the scale member 652 indicates the distance between the lower limit setting mechanism 651 and the support member 621 and the size of the sample drug 5a, and further indicates the regulated height by the second sorting member 620 adjusted by the manual adjustment mechanism 650. .. Further, since the measurement and display of the sample drug 5a are performed along with the vertical position adjustment of the support member 621, it also serves as a guideline for the adjustment of the first sorting member 610.
- Both of the two front-stage hanging objects 612 hang down above the drug transport path of the annular upper end surface 230, and are aligned in the transverse direction of the drug transport path, which is the radial direction of the annular upper end surface 230.
- the position of the lower end of the anterior hanging object 612 cannot be unequivocally determined because it depends on the adjustment policy, but in most cases, it is slightly smaller than the drug so that if the drugs overlap on the drug transport route, they interfere with the upper drug. Set high.
- the large ball 613 is heavy and the overlap of the drug is efficiently eliminated, but the large ball 613 at the lower end, which is the free end, escapes due to the deformation of the connecting portion immediately above, so that the impact on the drug is small.
- the drug When the drug is spherical, the drug rolls easily and the position is often unstable.
- the spherical drug is centrally located across the drug transport path, the drug slips between the side-by-side anterior droops 612.
- the drug when the drug is positioned slightly laterally from the center of the drug transport path, the drug is slightly interfered with the anterior hanging object 612 on the misaligned side, and the drug is centered (for a drug that easily rolls). It is brought closer to the widened portion 231A of the groove 231 of the annular upper end surface 230 of the outer rotating body 200 described above.
- the support member 621 of the two middle-stage hanging objects 622 is a straddling sorting member straddling the regulation mechanism 700, and any of the middle-stage hanging objects 622 hangs above the drug transport path of the annular upper end surface 230 and is regulated. It is located next to the mechanism 700 (particularly the second regulating member 720) and is a side-by-side hanging object.
- both of the two middle-stage hanging objects 622 are located above the drug transport path of the annular upper end surface 230, and they are lined up diagonally with respect to the drug transport path. Further, in a standard setting where the relationship between the support member 621 and the manual adjustment mechanism 650 is set, the lower end positions of the two middle hangers 622 are slightly lower than the drug on the drug transport path. Therefore, in the two middle-stage hanging objects 622, if the drugs overlap on the drug transport path, the middle ball 623 interferes with the upper drug to eliminate the overlap of the drugs. In addition, the two middle-stage hanging objects 622 return the drug, for example, isolated alone or slanted on the inner peripheral side of the drug transport path to the center of the drug transport path, or an inwardly inclined rotating body. By returning to 300, the function of strengthening the drug alignment function on the drug transport route is also exhibited.
- Two posterior hanging objects 632 hangs above the inner peripheral side of the drug transport path of the annular upper end surface 230, and the other (in the figure, the front).
- the seven objects deviate from above the drug transport path of the annular upper end surface 230 and hang down above the outer peripheral side of the inner inclined rotating body 300, and are lined up in the transverse direction of the drug transport path.
- the lower end position of one rear hanging object 632 is set to be slightly lower than the lower end position of the middle hanging object 622 described above, and the other rear hanging object 632 The lower end position is set even lower.
- the lower end positions of the first sorting member 610 in which the large balls 613 are connected, the middle-stage hanging object 622 in which the middle balls 623 are connected, and the rear-stage hanging object 632 in which the small balls 633 are connected are in the order of the ball dimensions. ing.
- At least the rear-stage hanging object 632 on the inner peripheral side is made of a magnetic material such as iron as the material of the small ball 633.
- a magnetic material such as iron as the material of the small ball 633.
- an attractive member 640 made of a permanent magnet or the like is attached to the second regulating member 720 by fitting or the like at a portion close to the rear hanging object 632. In this way, the attractive force of the attractive member 640 is applied to the component force of gravity, and the rear hanging object 632 exerts a gentle but effective reaction force against the drug that comes into contact with the drug from above the drug transport path. Let it work.
- Such a post-stage hanging object 632 emphasizes the strengthening of the width regulation of the drug of the second regulating member 720 rather than the height regulation function of its own drug.
- the internal space expansion body 800 shown in FIG. 6 is mounted on the peripheral wall of the housing 11 and expands the internal space 220 of the outer rotating body 200 upward.
- 6 (A) to 6 (C) show the structure of the internal space expansion body 800 of the drug feeder 100, FIG. 6 (A) is a perspective view, FIG. 6 (B) is a bottom view, and FIG. 6 (C). Is a side view.
- the internal space expansion body 800 is provided with a through hole 811 corresponding to the opening of the internal space 220 of the outer rotating body 200, and penetrates through a flange portion 810 fixed to a top plate 11A located on the peripheral wall 11C of the housing 11.
- the internal space expansion body 800 further includes a hanging portion 830 extending into the internal space 220 of the outer rotating body 200.
- the hanging portion 830 has the flange portion 810 fixed to the top plate 11A located at the upper end of the peripheral wall 11C of the housing 11, and the hanging portion 830 does not interfere with the regulation mechanism 700, the inner inclined rotating body 300, and the outer rotating body 200. It is located next to the regulation mechanism 700 and extends into the internal space 220.
- the flange portion 810 can be attached to and detached from the top plate 11A directly or indirectly via a plate body on which the discharge guide 13 is formed.
- the through hole 811 is located above the outer rotating body 200 and the inner inclined rotating body 300, and the tubular portion 820 protrudes slightly upward from the flange portion 810.
- the hanging portion 830 is inserted inside the outer rotating body 200 (at least inside the opening of the annular upper end surface 230), and the regulation mechanism 700 (particularly).
- the hanging portion 830 allows the medicine removed from the top of the annular upper end surface 230 in front of the discharge guide 13 to smoothly return onto the inner inclined rotating body 300.
- a bulge 812 is formed in a part of the through hole 811 (see FIG. 6B), and a bulge 821 is also formed in the corresponding portion of the tubular portion 820 connected to the bulge 812 (see FIG. 6B). 6 (A)).
- the bulges 812 and 821 make it possible to avoid undesired interference with the inner inclined rotating body 300 and smoothly deliver the drug from the inner inclined rotating body 300 to the outer rotating body 200.
- FIG. 7 (A) and 7 (B) show the overall structure of the two drug feeders 100, 100 in which the one equipped with the internal space expansion body 800 and the one not equipped with the internal space expansion body 800 are arranged side by side.
- FIG. 7B is an external perspective view of the drug feeder 100 with the cover 110 closed.
- the cover 110 is connected to the upper surface of the top plate 11A of the housing 11 or the plate body forming the discharge guide 13 via a hinge member, and covers or opens the upper portion of the top plate 11A.
- a bi-stable spring or the like is incorporated in the hinge member so that the cover 110 is stable in either the fully open state or the fully closed state.
- the cover 110 is made of a transparent or semi-transparent member so that the operating state of the inner inclined rotating body 300 and the like can be visually confirmed even when the cover 110 covers the upper part of the top plate 11A.
- the lower surface of the cover 110 approaches the upper end of the tubular portion 820 of the internal space expansion body 800 until just before contact.
- the depth of the cover 110 and the height of the interior space expansion body 800 are designed in association with each other.
- the hinge member When the hinge member is provided behind the drug feeder 100 (rear right in the figure) as shown in the figure and the cover 110 is lowered forward, the drug feeder 100 is closed and the drug feeder 100 that raises the cover 110 rearward is opened. It is easy to use even if a plurality of drug feeders 100 are arranged side by side, but it goes without saying that the plurality of covers 110 may be opened in different directions.
- FIG. 8A shows the internal structure of the drug feeder 100 incorporating the rotation drive mechanism 500.
- the controller 570 and the like (control unit) shown in FIG. 8B is a block configuration diagram related to rotation drive control.
- the rotation drive mechanism 500 shown in FIG. 8A includes a rotation drive member 511 and a rotation drive member 512 that replace the rotation drive member 51 shown in FIG. 11, and a rotation drive motor 541 that replaces the rotation drive motor 54 shown in FIG.
- a rotary drive motor 542, a newly added inner inclined rotating body mounting detecting means 550, and a designated drug drop detecting means 560 are provided.
- the rotary drive motor 541 rotates the outer rotating body 200 via the rotary drive member 511.
- the rotary drive motor 542 rotates the inner inclined rotating body 300 via the rotary drive member 512.
- the outer rotating body 200 and the inner inclined rotating body 300 can be independently driven.
- both the rotary drive motor 541 and the rotary drive motor 542 are adopted so that the direction of rotation can be selectively switched between forward rotation and reverse rotation according to the control of the controller 570. Therefore, the rotation drive mechanism 500 can individually reverse the rotation directions of the outer rotating body 200 and the inclined rotating body 300.
- the inner inclined rotating body mounting detection means 550 is composed of a photo sensor or the like attached to a shaft support portion of the rotating shaft portion 370 of the inner inclined rotating body 300.
- the rotating shaft portion 370 is located at the detection destination of the photo sensor, whereas when the inner tilting rotating body 300 is removed or mounted, the mounting state is inappropriate. , The rotating shaft portion 370 deviates from the detection destination of the photo sensor. As a result, the attachment / detachment of the inner inclined rotating body 300 can be detected.
- the drug drop detecting means 560 includes a photo sensor or the like that faces the drop path of the drug extending downward from the drop discharge port 14, is aligned with the annular upper end surface 230 of the outer rotating body 200, and is sequentially discharged through the drop path in order. Detects the falling state of the drug.
- the controller 570 is a control circuit (control means) mainly composed of a microprocessor, and is a set of rotary drives that can be independently driven by receiving various instructions such as initialization instructions and drug discharge instructions from an operation unit or a host device (not shown).
- the rotation of the motors 541 and 542 is controlled.
- the controller 570 adjusts the rotation direction and rotation speed of the rotation drive motor 541 and the rotation direction and rotation speed of the rotation drive motors 541 and 542 with reference to the presence / absence of the initialization instruction and the detection result of the drug drop detecting means 560. It is equipped with a drug discharge operation control program (drug discharge operation control means) for sequentially discharging drugs, and a drug number management program (drug number management means) for discharging the number of drugs specified in the drug discharge instruction. There is.
- the drug feeder 100 is attached / detached, immediately after the power is turned on, the drug feeder 100 is replenished or reset, and the initialization instruction issued after the drug discharge timeout is received, the drug is received. Clear the size estimate. Further, by monitoring the detection result of the inner inclined rotating body mounting detection means 550, it is determined whether or not the inner inclined rotating body 300 and the outer rotating body 200 are properly equipped, and only when the equipment is appropriate, the next Performs agent number management processing. That is, in this agent number management process, the drug discharge operation control program is activated, then the detection result of the drug drop detection means 560 is monitored to grasp the number of discharged drugs, and the number of drugs specified in the drug discharge instruction is increased. When the drug is discharged, the operation of the drug discharge operation control program is stopped.
- the above-mentioned estimated value of the drug size is confirmed, and when the estimated value is cleared, the initial operation before obtaining the estimated value of the drug size is performed.
- the rotation speed of the rotating container (200, 300) in which the outer rotating body 200 and the inner inclined rotating body 300 are combined is first switched from high speed to low speed.
- the preceding high-speed rotation is such that in the initial state drug feeder 100, the inner inclined rotating body 300 rotates a quarter of the estimated time until the first drug transfers from the inner inclined rotating body 300 to the outer rotating body 200, for example. Only time is done.
- the next low-speed rotation is performed at a low speed such that even the easily rolling drug does not excessively go to the drop discharge port 14 until the first drop drug is detected by the drug drop detection means 560. By doing so, it is possible to shorten the required time while avoiding excessive excretion even when the size of the drug is unknown.
- the drug drop detection means 560 detects a drug drop
- the drug number management program is notified that one drug has been discharged, but the estimated value of the drug size.
- the estimated value is also set. Specifically, the drug detection time length is measured at the time of the first detection of the falling drug, and the measured value is used as it is or a value obtained by multiplying the measured value by a predetermined constant is adopted as the estimated value of the drug size. This completes the initial operation.
- the control by the drug discharge operation control program performs a steady operation.
- the rotation speed of the rotary container (200, 300) is variably controlled according to the estimated value of the drug size. Specifically, for example, the reciprocal of the above estimated value is used as it is, or the value obtained by multiplying it by a constant is set as the control target value of the rotary container (200, 300) to perform feedback control.
- the control of the agent discharge operation control program does not stop the rotation of the rotating container (200, 300) suddenly in order to prevent excessive rolling of the agent. , Gradually slow down or rotate in reverse to prevent excessive drop of the drug.
- the reverse rotation of the rotating container is performed when the number of drugs specified in the drug discharge instruction has been discharged. Therefore, for example, when a drug discharge instruction is issued from a drug packaging machine of a higher-level device, a so-called reversal discharge operation is performed in units of one package.
- the usage mode and operation of the drug feeder 100 of such an embodiment will be described with reference to the drawings.
- the contents of the drug feeder 10 that follow the above-mentioned matters will be briefly described, and the details will be described below focusing on the improvements and new matters.
- the inner tilting rotating body mounting detecting means 550 can detect the rotating shaft portion 370 of the inner tilting rotating body 300. Instead, an alarm is issued accordingly. When the alarm is noticed, the outer rotating body 200 and the inner inclined rotating body 300 are set again.
- the cover 110 is opened (see FIG. 7A), and if the amount of the drug 5 does not exceed the capacity of the rotating container, the internal space is expanded. It is not necessary to attach the body 800 (see the drug feeder 100 in the front right of FIG. 7 (A)), but if the amount of the drug 5 exceeds the capacity of the rotating container, the internal space expansion body 800 is attached (see FIG. 7A).
- 7 (A) refer to the drug feeder 100 on the far left), and randomly charge the required number or more of the drugs 5 into the rotating container (note that the drawings of the drugs 5 are shown in FIGS. 12 and 13 described above. Since it conforms to, I omitted it here).
- the adjustment work related to the width regulation on the drug transport path by the regulation mechanism 700 and the adjustment related to the height regulation on the drug transport path by the sorting mechanism 600 (see FIG. 4). Work is done (see Figure 5). Even if the internal space expansion body 800 is attached, the sample storage 740 of the regulation mechanism 700 and the manual adjustment mechanism 650 of the sorting mechanism 600 are not hidden (see FIG. 7), so that the internal space expansion body 800 is also attached. It can be adjusted in the same way as when it is not.
- the height regulation adjustment by the second sorting member 620 of the sorting mechanism 600 is performed manually after placing another sample drug 5a on the lower limit setting mechanism 651. By lowering the mechanism 650 and sandwiching the sample drug 5a, it can be easily and accurately carried out. In most cases, this adjustment is sufficient, but if you want to make fine adjustments based on test runs or previous actual runs, remove the sample drug 5a if necessary and raise or lower the support member 621 slightly with reference to the scale. do it. Further (see FIGS. 5A and 5B), the height regulation adjustment by the first sorting member 610 of the sorting mechanism 600 is manually performed with reference to the scale member 652 indicating the size of the sample drug 5a. By making adjustments, this can also be done easily and accurately.
- the condition that the inner inclined rotating body mounting detection means 550 detects the rotation shaft portion 370 of the inner inclined rotating body 300 is imposed, so that the drug is sequentially discharged. Is performed only in a safe condition in which the rotating vessel (200, 300) is properly fitted (see FIG. 8 (A)).
- the drug discharge operation control of the drug discharge operation control program is performed under the drug number control of the drug number management program. It is said. Since the estimated value of the drug size is cleared at the beginning, the initial operation is performed, and the rotation of the rotating container (200, 300) starts from a high speed first. Although it is high speed, it is not so high that the brittle agent 5 causes damage such as collapse or chipping on the surface or the like. Then, by the time the first drug is transferred from the inner inclined rotating body 300 to the outer rotating body 200, the rotation of the rotating container (200, 300) becomes slow. Therefore, even if the first drug 5 is sent onto the outer rotating body 200 early, it does not lead to an undesired situation in which the easily rolling drug goes to the drop discharge port 14.
- the agent 5 runs up the inclined inner surface of the outer rotating body 200 due to the centrifugal force generated at the peripheral edge portion of the inner inclined rotating body 300.
- the delivery portion 340 of the outward downward inclination 341 is formed on the peripheral edge portion of the inner inclined rotating body 300 (see FIG. 1), when the delivering portion 340 descends with the rotation of the inner inclined rotating body 300, it is inside. The drug 5 falls from above the upper surface 320 of the inclined rotating body 300. Then, as the delivery portion 340 rises with the further rotation of the inner inclined rotating body 300, the agent 5 of the delivery portion 340 is pushed up by the rear pushing portion 350.
- the drug 5 can be carried onto the outer rotating body 200 by the inner inclined rotating body 300.
- the height of the push-up portion 350 is increased by adding the first convex portion 361 of the convex portion 360, and the delivery portion 340B Since the inner peripheral side is also raised by the second convex portion 362 of the convex portion 360, even if the rotation of the inner inclined rotating body 300 is extremely slow, there is a high probability that the drug 5 will rotate outward from the inner inclined rotating body 300. It is pushed up to the body 200 and transferred onto the annular upper end surface 230.
- the promoting means 321 formed of wavy irregularities composed of a plurality of linear grooves is formed on the relatively flat upper surface portion 320 of the upper surface of the inner inclined rotating body 300. Therefore, the agent 5 on the upper surface portion 320 changes the action direction of the frictional force of the promoting means 321 under the state where the inner inclined rotating body 300 rotates and the relative action direction of gravity changes. Then, the rotation of the inner inclined rotating body 300 is effectively agitated even if it is slow. Therefore, the tablet slides from the upper surface portion 320 to the delivery portion 340. Further, since the delivery portions 340A and 340B are also formed with wavy irregularities similar to those of the accelerating means 321. Many collapse quickly. As a result, when the agent 5 is transferred from the inner inclined rotating body 300 to the annular upper end surface 230 of the outer rotating body 200, the amount of the agent 5 in a state where a plurality of the agents are vertically overlapped is considerably reduced.
- the drug 5 on the annular upper end surface 230 of the outer rotating body 200 (see FIG. 2 (A)) is stable in a wide groove when it rolls to reach the groove 231 if it is easy to roll (see FIG. 2 (A)).
- 2 (B), see FIG. 3) even those that are difficult to roll are stabilized by light interference at the groove 231 and sorted in order by the cyclic movement of the annular upper end surface 230 forming the drug transport path (see FIG. 5 (A)).
- the inner peripheral side of the first regulating member 710 of the regulating mechanism 700, the second regulating member 720 of the regulating mechanism 700, and the second sorting member of the sorting mechanism 600 Under the front hanging object 612 of the first sorting member 610 of the mechanism 600, the inner peripheral side of the first regulating member 710 of the regulating mechanism 700, the second regulating member 720 of the regulating mechanism 700, and the second sorting member of the sorting mechanism 600.
- the outer peripheral side of the discharge guide 13, and the drop discharge It is transported to the outlet 14.
- the annular upper end surface 230 is tilted by an angle ⁇ in a direction that raises the position of the drop discharge port 14 (see FIG. 2C), so that the component force of gravity pushes back the drug 5. Try to.
- the component force is small and smaller than the propulsive force due to the interference of the groove 231 or the like, the easily rolling agent 5 is also conveyed without any inconvenience.
- the drug transport status will be described in detail step by step.
- the interfering drug 5 may be moved between the two front-stage hanging objects 612, that is, in the center of the drug transport path, or pushed toward the inner circumference side from the drug transport path and returned onto the inner inclined rotating body 300. many. Further, the interference at that time is such that the front-stage hanging object 612 is deformed and easily escapes, so even if the drug 5 is fragile, the drug 5 is not easily broken. As described above, at the front stage hanging object 612, the height of the drug 5 is loosely regulated, and the distribution in the lateral width direction is also performed depending on the situation.
- a lower portion 711 having a width regulating function is provided on the inner peripheral side surface portion of the first regulating member 710. Since it is formed (see FIG. 4C), with respect to the two side-by-side drugs 5 and 5, the drugs on the inner peripheral side are pushed out from the drug transport path toward the inwardly inclined rotating body 300 by the lower portion 711. Or the two drugs will be rearranged back and forth on the drug transport route. Further, since the upper portion 712 that has a height regulating function is also formed on the inner peripheral side surface portion of the first regulating member 710 (see FIG. 4C), the drugs that are on the other drugs 5 and others.
- the ride between the two drugs 5 is eliminated. Since the ride-on between the two agents 5 has already been eliminated to some extent by the first sorting member 610, it is almost eliminated by the first regulating member 710.
- the single drug 5 is slightly smaller than the middle-stage hanging object 622.
- the interference between the middle pendant 622 and the drug is weak, the drug is transported without being hindered from the progress of the drug.
- the drug that is riding on the other drug 5 and the drug 5 that is leaning on it interfere more strongly with the middle-stage drooping object 622 than when the single drug 5 is used, so that the riding is often eliminated. ..
- the middle-stage hanging object 622 is more easily deformed and escapes than the front-stage hanging object 612, even if the drug 5 is brittle, the drug 5 is not easily broken. Further, the interfering drug 5 is pushed toward the inner circumference side from the drug transport path and returned onto the inner inclined rotating body 300, or is attracted to the second sorting member 620 and stays on the drug transport path.
- the attractive force of the attractive member 640 is applied, even when the rear hanging object 632 sways, the sway is suppressed by the attractive force of the attractive member 640 and is immediately settled. As a result, the urging of the drug 5 toward the second sorting member 620 is stable.
- the front-stage hanging object 612, the first regulating member 710, the middle-stage hanging object 622, the rear-stage hanging object 632, and the second regulating member 720 regulate the height and width of the drug.
- the drug 5 on the annular upper end surface 230 of the outer rotating body 200 is placed on the drug transport path by the height regulation and the width regulation of the drug which are repeated many times in multiple steps regardless of the state of coarseness and density. Become a line.
- the drug 5 comes to the outer peripheral side of the discharge guide 13 (see FIG. 5A)
- the drug 5 falls along the outer peripheral side surface of the discharge guide 13 as the outer rotating body 200 rotates. Is sent to.
- the hard-to-roll chemicals such as a disk move on the annular upper end surface 230 while maintaining a stable state due to friction with the annular upper end surface 230, and thus enter the drop discharge port 14 one by one.
- the easily rolling chemical such as a spherical shape is pushed by the discharge guide 13 and moves from the widening portion 231A of the groove 231 of the annular upper end surface 230 of the outer rotating body 200 to the inclined surface 232 of the annular upper end surface 230 via the tip end side of the groove 231.
- the drug 5 that has entered the drop discharge port 14 falls in a substantially free fall state along the fall path (see FIG. 8 (A)), and passes through the detection destination of the drug drop detection means 560.
- the estimated value of the drug size is cleared, that is, when the drug 5 is the first excreted drug
- the drug size is estimated according to the detection time length when the transit time at that time is detected. Further, based on the estimated value of the drug size, the subsequent rotation speed of the rotary drive motor 540 and the rotation speed of the rotary container (200, 300) are set.
- the rotating container (200,300) when the estimated value of the drug size is large, the rotating container (200,300) is rotated at high speed, but when the estimated value of the drug size is small, the rotating container (200,300) is rotated at a low speed.
- the setting is done automatically. After that, the rotating container (200, 300) rotates at the set speed. Therefore, for smaller drugs, undesired multiple drops can be prevented by lowering the speed, and for larger drugs, efficiency can be improved by increasing the speed.
- the controller 570 each time the drug drop detecting means 560 detects a drug drop, the controller 570 notifies the drug discharge operation control program to the drug number management program that one drug has been discharged. Then, when it is confirmed by the drug number management program that the number of times of drug discharge has reached the indicated value of the drug discharge instruction, the drug number management program issues an instruction to stop the discharge operation to the drug discharge operation control program. When this instruction is issued, the operation of the rotary drive motor 540 is stopped by the control of the drug discharge operation control program, so that the drug discharge operation is stopped. In this way, the number of drugs 5 specified in the drug discharge instruction is sent out from the drug feeder 100, and the drug supply according to one drug discharge instruction is completed quickly and accurately.
- the internal space expansion body 800 is attached to the drug feeder 100 (see the object on the left back side of FIG. 7A), and the outer rotating body is there. A description will be added about the operation when the drug 5 is charged up to a height of more than 200.
- the sorting mechanism 600 or the regulation mechanism 700 returns the internal space expansion body 800 from the drug transport path on the annular upper end surface 230 of the outer rotating body 200 to the inner inclined rotating body 300.
- the drug 5 (see FIG. 5 (A)) is formed by the inner peripheral wall surface of the outer rotating body 200 (see FIG. 2 (A)) and the outer peripheral surface of the hanging portion 830 of the internal space expansion body 800 (see FIG. 6). After being settled in the gap, it is returned to the lower side of the through hole 811 of the internal space expansion body 800 by the inner inclined rotating body 300.
- the upper surface inclined portion 330 is formed with a delivery portion 340, a push-up portion 350, and even a convex portion 360. Therefore, the agent 5 carried by the inner inclined rotating body 300 is an internal space expansion body. Even in a situation where it is submerged under a large number of agents 5 in 800, it is accurately delivered.
- the control method of the controller 570 will be described.
- the controller 570 not only the discharge operation mode in which the outer rotating body 200 and the inner inclined rotating body 300 are driven at the same time in the forward and reverse directions, but also one of the outer rotating body 200 and the inner inclined rotating body 300 is sequentially reversed.
- the discharge operation mode can also be selected.
- only the inner inclined rotating body 300 is slightly reversely rotated each time even one discharge of the drug 5 is detected.
- excessive discharge of the easily rolling drug 5 is accurately prevented without slowing down the transport speed of the drug transport path on the annular upper end surface 230 of the outer rotating body 200, and further, stirring that cannot be obtained by normal rotation alone is possible.
- the effect can also be exerted by reversing.
- the convex portion 360 provided on the push-up portion 350 of the inner inclined rotating body 300 exhibits a large stirring effect even at the time of reversal.
- the ratio of reversal to forward rotation is not limited to each time as described above, and is appropriately selected such as one reversal for every two normal rotations and one reversal for every several normal rotations. You may be able to do it.
- the drug handled by the drug feeder 100 is changed, if the drug still remains in the drug feeder 100, the remaining drug is collected, but the drug feeder 100 has Two means of collecting residual drug are provided.
- the first is to continuously reverse the rotating container (200, 300) for a sufficient time.
- the medicine on the outer rotating body 200 is regulated by the sorting mechanism 600 at the time of reversing.
- the mechanism 700 is pushed inside the outer rotating body 200 by the extension surface on the inner peripheral side of the discharge guide 13, and gathers on the inner inclined rotating body 300.
- the collected medicine is taken out manually.
- the second is to continuously rotate the rotating container (200,300) in the normal direction until the discharge is completed.
- the discharged drug is collected in a collection container or the like and incorporated into a packing machine. When using, enclose it in a packing paper and collect it.
- the sample drug 5a will also be replaced.
- the set sample drug 5a must be removed, but since the small lid 741 of the sample storage 740 of the regulatory mechanism 700 is transparent, the presence or absence and shape of the sample drug 5a placed there can be visually checked. Since it is easy and sure to understand, undesired forgetting to take it is unlikely to occur. The same applies to the sample drug 5a placed in the manual adjustment mechanism 650 of the sorting mechanism 600, because it is not sealed by the sandwiching method and is visible.
- the degree of "overrun that causes excessive discharge” due to this deceleration can be reduced as compared with the case without deceleration. Then, in response to the detection of the fall discharge of the drug whose discharge is completed (last) that occurs immediately after that, the outer rotating body 200 promptly suspends the rotation, or reversely rotates (reverses, reverses) after the stop. Since the next drug moves away from the drop / discharge port 14, undesired discharge of excess drug (multi-tablet drop) is less likely to occur.
- the unevenness (234,235) of the scattered spot pattern between the two adjacent grooves 231 and 231 prevents or suppresses the undesired slippage of the drug that tends to occur when the annular upper end surface 230 is decelerated or reversed. It is possible to speed up the discharge of chemicals while avoiding excessive discharge of the drug.
- the time is defined as the “time lag”
- the time required to decelerate and stop the rotation of the outer rotating body 200 without sliding the chemical on the upper surface is defined as the “deceleration time”
- the number of similar chemicals contained in one package is ".
- the outer rotating body 200 prevents an overrun in which the drug in the next package is undesirably dropped and discharged. The rotation must be decelerated quickly and then stopped.
- the N-1th drug from the beginning is swiftly performed at an appropriate constant speed, and N- From the detection of the discharge of the first drug to the detection of the discharge of the last Nth drug, the above-mentioned unevenness of the scattered spot pattern (234,235) improves the anti-slip function of the drug.
- the speed is reduced from the above constant speed to 60%. In this way, by narrowing down the deceleration target to the last drug in the package and allowing it to be transported gently only at that time, the occurrence of overrun is suppressed in situations where overrun is a problem. , The drug to be included in the next packet will remain on the outer rotating body 200 without being dropped and discharged. Therefore, it is possible to accurately detect the falling discharge of the drug in one package up to the last drug while minimizing the decrease in efficiency due to deceleration.
- the outer rotating body 200 is rotated in the opposite direction by, for example, about 3 °. It has become.
- the reversal (reverse rotation) of the outer rotating body 200 is performed in response to the drop detection of the "last drug in one package", and immediately before that, the rotation speed of the outer rotating body 200 is about 60%.
- the speed is reduced to the above, the occurrence of overrun is suppressed as described above. Therefore, at the time of reversal, the drug is quickly sufficiently separated from the drop discharge port 14 while avoiding undesired slippage of the drug in the next package. The next package of drugs can be returned to the safe area.
- the outer rotating body 200 rotates in the original transport direction by reversing. Therefore, the first drug in the next package is quickly dropped and discharged at the rotation speed of the outer rotating body 200 arbitrarily set from the "position in a safer zone" that is surely separated from the drop discharge port 14. It is sent to the exit 14. Even if the first drug in the next package is far from the drop outlet 14 to the safe area, the amount of reversal is suppressed to about 3 °, and the scattering point between the grooves 231 and 231 is also during acceleration at that time. Since the undesired slippage of the drug is prevented / suppressed by the unevenness of the pattern (234,235), the drug in the next package is also appropriately and promptly discharged.
- the sample drug 5a selected from the drug 5 was placed in the sample storage 740 of the manual adjustment mechanism 650 of the second sorting member 620 and the regulation mechanism 700, but the sample drug 5a is selected from the drug 5. It is not limited to those that have been prepared, and may be a substitute other than a drug as long as the main parts have the same dimensions.
- the support member 621 of the second sorting member 620 is a straddling sorting member
- the support member 611 of the first sorting member 610 is not a straddling sorting member. This is not essential, and may be a straddling sorting member up to the support member 611 of the first sorting member 610.
- the ratio of reversing to normal rotation may be further increased. Since the convex portion 360 is formed on the inner inclined rotating body 300 described above, the inner inclined rotating body 300 can push up the drug 5 and deliver it to the outer rotating body 200 even at the time of reverse rotation, so that the forward rotation and the reverse rotation By alternately repeating the above steps at an appropriate ratio, the drug 5 in the rotating container (200, 300) can be delivered while being thoroughly stirred.
- the inner inclined rotating body mounting detecting means 550 a photosensor incorporated in the shaft support portion of the rotating shaft portion 370 of the inner inclined rotating body 300 has been exemplified, but the inner inclined rotating body mounting detecting means 550 is appropriate. Other sensors may be used as long as they can detect the inwardly inclined rotating body 300 mounted in a proper posture, and for example, a mechanical switch may be used.
- the mounting location of the inner inclined rotating body mounting detecting means 550 is not limited to the shaft support portion of the rotating shaft portion 370, and may be, for example, a support plate of the rotary drive motors 541 and 542, and the rotary drive motor 541 may be mounted. , 542 may be an intermediate position.
- the detection method is not limited to the one that directly detects the rotating shaft portion 370, and may be indirectly detected via an appropriate link member or the like.
- the rotary drive motors 541 and 542 are displayed smaller than the rotary drive members 511 and 512, but the rotary drive motors 541 and 542 may be larger and the rotary drive members may be larger. 511 and 512 may be smaller. Further, while the rotary drive motor 541 and the rotary drive member 511 are not tilted, the rotary drive motor 542 and the rotary drive member 512 are tilted, but it is arbitrary whether or not they are tilted in any of the installations. Further, the left-right position of the rotation drive motor 541 and the rotation drive member 511 and the left-right position of the rotation drive motor 542 and the rotation drive member 512 are also arbitrary design items.
- the drug feeder of the present invention may be used to replace some or all of the large number of aligning disc rotating type drug feeders mounted on the tablet packaging machine, and mounts only one or a small number of drug feeders. It may be mounted on a tablet divider, or may be mounted on a tablet counter (drug counter) that counts the number of drugs sequentially delivered in a device for filling a drug bottle with a drug such as a tablet.
- a tablet counter drug counter
- Middle stage hanging object (side by side hanging object), 623 ... Middle ball, 632 ... Rear hanging objects (side by side hanging objects), 633 ... Small balls, 640 ... Attractive members, 650 ... Manual adjustment mechanism, 651 ... Lower limit setting mechanism, 652 ... Scale member, 700 ... Regulatory mechanism, 710 ... 1st regulatory member, 711 ... lower part, 712 ... upper part, 720 ... Second regulatory member, 721 ... Lower part, 722 ... Upper part, 730 ... Spring (biasing member), 740 ... Sample storage, 741 ... Small lid (transparent member), 742 ... Set screw (fixing member), 800 ... Internal space extension, 810 ... Flange part, 811 ... Through hole, 820 ... Cylinder part, 830 ... Hanging
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mechanical Engineering (AREA)
- Engineering & Computer Science (AREA)
- Feeding Of Articles To Conveyors (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
外側回転体200の回転制御をコントローラ570が行う際に一包分の薬剤を排出し終える前に減速制御を行うとともに一包分の薬剤を排出し終えた後に逆回転制御を行うことについて、既述したものと重複する事項もあるが、ここで纏めて説明する。一包分の薬剤が複数個のとき、当初は薬剤を整列しうる適宜な速度で外側回転体200が回転して速やかに薬剤の逐次排出と排出薬剤の検出が繰り返されるが、排出完了直前(最後の一つ手前)の薬剤に係る落下排出が検出されると、それに応じて外側回転体200の回転が減速する。この減速によって「過剰排出を招くオーバーラン」の度合いが、減速無しのときと比べて小さく済む。そしてその直後に生じる排出完了(最後)の薬剤に係る落下排出の検出に応じて、速やかに外側回転体200が回転を一時停止するかまたは、停止後に逆回転(逆転、反転)することで、次の薬剤が落下排出口14から遠ざかるため不所望な過剰薬剤の排出(多錠落下)が起きにくくなる。
上記実施例では、第2仕分け部材620の手動調整機構650や規制機構700のサンプル置場740に、薬剤5から選出したサンプル用薬剤5aを置いていたが、サンプル用薬剤5aは、薬剤5から選出したものに限られる訳でなく、要部寸法が同じであれば薬剤以外の代用品であっても良い。
10…薬剤フィーダ、
11…周壁、12…搬送面ガイド、13…排出ガイド、14…落下排出口、
20…外側回転体、21…下部、22…上部、23…環状上端面(薬剤搬送経路)、
30…内側傾斜回転体、31…中央突起、32…央部、33…周縁部、40…支承機構、
41…受動部材、
42…大径部外装回転伝動部材、43…小径部外装回転伝動部材、
50…回転駆動機構、51…回転駆動部材、
52…大径部、53…小径部、54…回転駆動モータ、
60…仕分け部材、61…基端部、62…先端部(薬剤当接部位)、63…支持部、
70…規制機構、71…第1規制部材、72…第2規制部材、
73…リンク機構、74…サンプル置場、
100…薬剤フィーダ、
110…カバー、
200…外側回転体、
201…縦線、210…下部、220…上部、
230…環状上端面(薬剤搬送経路)、
231…溝、232…傾斜面、233…凹部、
300…内側傾斜回転体、
310…本体、320…上面部、
330…上面周縁部、340…引き渡し部、350…押し上げ部、351…央部延長面、
360…凸部、361…基部、362…延伸部、370…回転軸部、
500…回転駆動機構、
511,512…回転駆動部材、541,542…回転駆動モータ、
550…内側傾斜回転体装着検出手段、560…薬剤落下検出手段、
570…コントローラ(制御手段)、
610…第1仕分け部材、611…支持部材、612…前段垂下物、613…大玉、
620…第2仕分け部材(跨ぎ仕分け部材)、
621…支持部材(跨ぎ部)、622…中段垂下物(横並び垂下物)、623…中玉、
632…後段垂下物(横並び垂下物)、633…小玉、640…引き付け部材、
650…手動調整機構、651…下限設定機構、652…目盛部材、
700…規制機構、
710…第1規制部材、711…下段部分、712…上段部分、
720…第2規制部材、721…下段部分、722…上段部分、
730…バネ(付勢部材)、740…サンプル置場、
741…小蓋(透明部材)、742…止めネジ(固定部材)、
800…内部空間拡張体、
810…フランジ部、811…貫通穴、820…筒部、830…垂下部
Claims (38)
- 上方に向かって開口する開口部を有する内部空間及び前記開口部を囲む環状上端面を備え、前記内部空間内を上下方向に延びる仮想の縦線を中心として回転可能な外側回転体と、
前記外側回転体の前記内部空間内に配置され、複数の固形の薬剤を上面部に載せた状態で、前記縦線に対して傾いた仮想の傾斜線を中心として回転可能で、回転しているときに前記複数の薬剤を前記外側回転体の前記環状上端面上に移動させる内側傾斜回転体と、
前記外側回転体の前記環状上端面上に移動した複数の薬剤を、前記外側回転体が回転しているときに前記環状上端面の回転方向に沿って整列させる規制機構とを備えた薬剤フィーダであって、
前記内側傾斜回転体の前記上面部の周縁領域には、上昇位置でも外側に向かって下がっている外下がり傾斜を有する複数の引き渡し部と、前記外下がり傾斜を有しない複数の押し上げ部とが、周方向に1つずつ交互に形成されており、
前記複数の引き渡し部は、それぞれ前記上昇位置で前記外下がり傾斜上に1以上の前記薬剤が乗っていれば前記外下がり傾斜を利用して該薬剤を前記外側回転体の前記環状上端面上へ乗り移らせうるものであり、
前記押し上げ部は、前記内側傾斜回転体の順回転方向の前方に位置する前記引き渡し部にある前記1以上の薬剤を前記上昇位置まで押し上げうるものであることを特徴とする薬剤フィーダ。 - 前記上昇位置は、前記内側傾斜回転体の前記引き渡し部の前記外下がり傾斜の端縁が、前記環状上端面と一致する位置か前記環状上端面よりも上にある位置である請求項1に記載の薬剤フィーダ。
- 前記引き渡し部の全領域において、前記外下がり傾斜の傾斜角度は一定であり、
前記押し上げ部は、前記内側傾斜回転体の逆回転方向に位置する前記引き渡し部の端部に連続して形成された立ち上がり部分を含んでいることを特徴とする請求項1記載の薬剤フィーダ。 - 前記立ち上がり部分は、前記下がり傾斜と連続して前記仮想の傾斜線が延びる方向と同じ方向に延びる立ち上がり面を有している請求項3に記載の薬剤フィーダ。
- 前記複数の引き渡し部は、前記周縁領域の周方向に交互に並ぶ第1の引き渡し部と第2の引き渡し部からなり、
前記第1の引き渡し部は、前記内側傾斜回転体の前記上面部と前記下がり傾斜とが連続する構造を有しており、
前記内側傾斜回転体は、前記周縁領域に隣接する前記上面部の第1の部分から突出する第1の凸部部分と該第1の部分と連続して前記上面部の外周縁まで延びる第2の部分から突出する第2の凸部部分とからなる凸部を有しており、
前記第2の引き渡し部は、前記第1の凸部部分の外面まで前記下がり傾斜の少なくとも一部が延びる構造を有しており、
前記立ち上がり部分の前記立ち上がり面が、前記第2の凸部分の外面まで延びている請求項4に記載の薬剤フィーダ。 - 前記内側傾斜回転体の前記上面部のうち前記周縁領域より内側の部分には、前記内側傾斜回転体の前記周方向に摩擦力を発生して前記上面部上の複数の薬剤の撹拌を促進し且つ前記第1の引き渡し部に向かう方向への前記薬剤の転動を促す促進手段が設けられている請求項1乃至5のいずれか1項に記載の薬剤フィーダ。
- 前記促進手段は、前記周方向に並び且つ前記第1の引き渡し部に向かって延びる複数の波状凹凸からなる請求項6に記載の薬剤フィーダ。
- 前記外側回転体の前記上面部上で整列後に排出される前記薬剤の落下を検出する落下薬剤検出手段と、
前記落下薬剤検出手段の出力から前記薬剤の落下間隔を検出し、その検出結果に応じて前記内側傾斜回転体及び前記外側回転体の少なくとも一方の回転を制御するコントローラを更に備え、
前記コントローラは、前記内側傾斜回転体及び前記外側回転体の回転方向とを個別に反転しうる機能を有しており、前記外側回転体を順方向に回転させつつ前記落下薬剤検出手段が検出する薬剤落下検出に応じて前記内側傾斜回転体を一時的に逆転させることを特徴とする請求項1乃至7の何れか1項に記載の薬剤フィーダ。 - 前記規制機構の後方に設けられていて前記外側回転体の前記環状上端面上の前記薬剤を前記環状上端面の内周側から外周側へ導いて落下排出口へ送り込む排出ガイドを更に備え、
前記外側回転体は、前記環状上端面上に周方向に所定の間隔をあけて並ぶ複数の溝を備えており、前記複数の溝は、それぞれ径方向に延びており且つ径方向の途中に幅寸法が広がった拡幅部を備えており、
また前記複数の溝は前記拡幅部よりも前記環状上端面の内周縁及び外周縁に向かうに従って幅寸法が小さくなる形状を有している請求項1に記載の薬剤フィーダ。 - 前記複数の溝は、前記内周縁に達していることを特徴とする請求項9に記載の薬剤フィーダ。
- 前記外側回転体の前記環状上端面には、隣り合っている2つの前記溝の間に、前記内周縁に近付くほど深さが深くなる湾状の凹部が形成されており、前記凹部は前記内周縁側では前記径方向内側に開口していることを特徴とする請求項9または10に記載の薬剤フィーダ。
- 前記コントローラは、前記落下薬剤検出手段により排出完了直前の一つの薬剤に係る落下排出が検出されると、外側回転体の回転速度を減速し、前記落下薬剤検出手段により最後の薬剤の排出完了が検出されると、外側回転体の回転を一時停止するかまたは一時逆回転させる制御行うことを特徴とする請求項8に記載の薬剤フィーダ。
- 前記外側回転体の前記環状上端面の前記外周縁には一周に亘って径方向の外側に向かうに従って下がる環状の傾斜面が形成されており、
前記複数の溝は、前記環状の傾斜面内まで延びている請求項8に記載の薬剤フィーダ。 - 前記外側回転体の回転中心となる前記仮想の縦線が鉛直線から角度βだけ傾斜しており、前記仮想の縦線の傾斜方向が前記外側回転体のうち前記落下排出口寄りの部位を高める向きになっており、
前記角度βが前記傾斜面の傾斜角度αより小さいことを特徴とする請求項9に記載の薬剤フィーダ。 - 隣り合っている前記溝の間に散点模様の複数の凹凸が形成されていることを特徴とする請求項9に記載の薬剤フィーダ。
- 前記外側回転体の前記環状上端面の前記外周縁には、一周に亘って径方向の外側に向かうに従って下がる環状の傾斜面が形成されており、
前記複数の凹凸が前記凹部と前記環状の傾斜面との間にも形成されていることを特徴とする請求項11に記載の薬剤フィーダ。 - 前記溝と前記凹部と前記傾斜面とによって囲まれた領域に前記複数の凹凸が形成されていることを特徴とする請求項11に記載の薬剤フィーダ。
- 前記内側傾斜回転体の回転によって前記外側回転体の前記環状上端面の上に運ばれた固形の複数の薬剤を前記外側回転体の回転時に整列させる仕分け機構を更に備えており、
前記仕分け機構が前記外側回転体の前記環状上端面の上の前記複数の薬剤に対して高さを規制するように構成されており、
前記規制機構が前記外側回転体の前記環状上端面の上の前記複数の薬剤に対して横幅方向の位置を規制するとともに高さも規制するように構成されている請求項1に記載の薬剤フィーダ。 - 前記規制機構は、前記外側回転体の前記環状上端面の上の薬剤搬送経路幅を外周側から狭めるものであって、
前記規制機構は、前記環状上端面と所定の間隔をあけて対向する高さ規制部と、前記環状上端面上に張り出て前記薬剤搬送経路幅を規制する幅規制部とを備えていることを特徴とする請求項18記載の薬剤フィーダ。 - 前記規制機構は前記薬剤の横幅寸法に対応して前記薬剤搬送経路幅を可変調整するために前記幅規制部を可変調整する機構を備えている請求項19に記載の薬剤フィーダ。
- 前記仕分け機構が、前記外側回転体の前記環状上端面の上方から垂れ下がっていて下端部を横に押されると変形しうる1以上の垂下物を具備しており、
前記垂下物が前記環状上端面の上の薬剤に対して高さを規制するようになっていることを特徴とする請求項18に記載の薬剤フィーダ。 - 前記垂下物が複数の玉または球体を緩く連結したものであることを特徴とする請求項19に記載の薬剤フィーダ。
- 前記1以上の垂下物が複数の垂下物からなり、前記複数の前記垂下物が前記外側回転体の径方向位置を異にしていることを特徴とする請求項21または22に記載された薬剤フィーダ。
- 前記1以上の垂下物が複数の垂下物からなり、前記複数の垂下物が前記外側回転体の周方向位置を異にしていることを特徴とする請求項21または22に記載された薬剤フィーダ。
- 前記1以上の垂下物が、前記外側回転体の径方向外側に一端が装着されて前記規制機構の上を延びる支持部材の他端から垂れ下がっている垂下物を含む請求項23または24に記載の薬剤フィーダ。
- 前記垂下物が前記規制機構の横に位置しており、前記垂下物に引き付け力を働かせる引き付け部材が前記規制機構に付設されていることを特徴とする請求項24に記載された薬剤フィーダ。
- 前記複数の垂下物にサイズの異なるものが含まれていることを特徴とする請求項21乃至26の何れか1項に記載された薬剤フィーダ。
- 前記複数の垂下物のうち前記玉のサイズが大きいものは前記玉のサイズが小さいものより下端位置が高くなっていることを特徴とする請求項27に記載の薬剤フィーダ。
- 前記仕分け機構による規制高さを手動操作にて可変調整しうる手動調整機構と、その調整範囲の下限を前記薬剤またはその代用品の挟持にて機械的に設定しうる下限設定機構とが更に設けられていることを特徴とする請求項18に記載された薬剤フィーダ。
- 前記手動調整機構によって調整された前記仕分け機構による規制高さを示す目盛部材が更に設けられていることを特徴とする請求項29に記載の薬剤フィーダ。
- 前記外側回転体を内部に回転可能に収めた周壁を有するハウジングと、
前記ハウジングの周壁の上に装着されて前記外側回転体の前記内部空間を上方に拡張する内部空間拡張体を更に備えている請求項1に記載の薬剤フィーダ。 - 前記内部空間拡張体は、前記外側回転体の前記内部空間の前記開口部に対応する貫通穴を備えて前記周壁の上端部に固定されるフランジ部と、前記貫通穴の周縁部から起立して前記内部空間を上方に延長するように前記フランジ部の上方に延びる筒部とを具備している請求項31に記載の薬剤フィーダ。
- 前記内部空間拡張体は前記外側回転体の前記内部空間内に延びる垂下部を更に備えており、
前記垂下部は前記フランジ部を前記周壁の前記上端部に固定した状態で、前記垂下部が前記規制機構、前記内側傾斜回転体及び前記外側回転体と干渉しないように前記規制機構の横に位置して、前記内部空間内に延びていることを特徴とする請求項32記載の薬剤フィーダ。 - 整列後に排出される薬剤の落下を検出する落下薬剤検出手段と、
前記落下薬剤検出手段の検出に応じて前記外側回転体の回転速度を可変制御するコントローラを更に備え、
前記コントローラは、前記落下薬剤検出手段の出力から1つの前記薬剤が落下するときの時間長を検出して前記薬剤の薬剤サイズを推定する機能と、前記薬剤サイズの推定値に応じて前記外側回転体の回転速度を変更する機能とを有することを特徴とする請求項1に記載の薬剤フィーダ。 - 前記コントローラが、前記推定値を得る前の初期動作時には前記外側回転体及び前記内側傾斜回転体の回転速度を高速から始めて低速に変更させるようになっていることを特徴とする請求項34に記載の薬剤フィーダ。
- 前記コントローラが、前記推定値を得た後の回転速度変更に際して前記推定値の大小に応じて前記回転速度の高低を定めるようになっていることを特徴とする請求項34に記載の薬剤フィーダ。
- 前記内側傾斜回転体及び前記外側回転体を回転させる回転駆動機構を更に備え、前記回転駆動機構は、前記コントローラからの指令に応じて、前記内側傾斜回転体の回転方向と前記外側回転体の回転方向とを個別に反転しうるものであり、
前記コントローラが、前記外側回転体を正転させているときで、前記落下薬剤検出手段が薬剤落下を検出しているときに、前記内側傾斜回転体を一時的に逆転させる機能を有していることを特徴とする請求項8または34に記載の薬剤フィーダ。 - 上方に向かって開口する開口部を有する内部空間及び前記開口部を囲む環状上端面を備え、前記内部空間内を上下方向に延びる仮想の縦線を中心として回転可能な外側回転体と、
前記外側回転体の前記内部空間内に配置され、複数の固形の薬剤を上面部に載せた状態で、前記縦線に対して傾いた仮想の傾斜線を中心として回転可能で、回転しているときに前記複数の薬剤を前記外側回転体の前記環状上端面上に移動させる内側傾斜回転体と、
前記外側回転体の前記環状上端面上に移動した複数の薬剤を、前記外側回転体が回転しているときに前記環状上端面の回転方向に沿って整列させる規制機構と、
整列後に排出される薬剤の落下を検出する落下薬剤検出手段と、
所定個数の薬剤を排出するように、前記落下薬剤検出手段の検出に応じて前記外側回転体の回転速度及び回転方向を制御するコントローラを備え、
前記コントローラは、前記落下薬剤検出手段により排出完了直前の一つの薬剤に係る落下排出が検出されると、外側回転体の回転速度を減速し、前記落下薬剤検出手段により最後の薬剤の排出完了が検出されると、外側回転体の回転を一時停止するかまたは一時逆回転させる制御行うことを特徴とする薬剤フィーダ。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/795,695 US11759396B2 (en) | 2020-01-29 | 2021-01-28 | Medicine feeder |
CA3169692A CA3169692A1 (en) | 2020-01-29 | 2021-01-28 | Medicine feeder |
CN202180011421.2A CN115038422A (zh) | 2020-01-29 | 2021-01-28 | 药剂供给器 |
EP21747412.1A EP4098594A4 (en) | 2020-01-29 | 2021-01-28 | DRUG ADMINISTRATION |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020012192A JP7281145B2 (ja) | 2020-01-29 | 2020-01-29 | 薬剤フィーダ |
JP2020012231A JP7337382B2 (ja) | 2020-01-29 | 2020-01-29 | 薬剤フィーダ |
JP2020-012127 | 2020-01-29 | ||
JP2020012424A JP7325756B2 (ja) | 2020-01-29 | 2020-01-29 | 薬剤フィーダ |
JP2020012127A JP6736075B1 (ja) | 2020-01-29 | 2020-01-29 | 薬剤フィーダ |
JP2020-012424 | 2020-01-29 | ||
JP2020012086A JP6736074B1 (ja) | 2020-01-29 | 2020-01-29 | 薬剤フィーダ |
JP2020-012086 | 2020-01-29 | ||
JP2020-012192 | 2020-01-29 | ||
JP2020-012315 | 2020-01-29 | ||
JP2020-012231 | 2020-01-29 | ||
JP2020012315A JP7337383B2 (ja) | 2020-01-29 | 2020-01-29 | 薬剤フィーダ |
JP2020-124675 | 2020-07-21 | ||
JP2020124675A JP7337388B2 (ja) | 2020-07-21 | 2020-07-21 | 薬剤フィーダ |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021153674A1 true WO2021153674A1 (ja) | 2021-08-05 |
Family
ID=77079133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/003052 WO2021153674A1 (ja) | 2020-01-29 | 2021-01-28 | 薬剤フィーダ |
Country Status (5)
Country | Link |
---|---|
US (1) | US11759396B2 (ja) |
EP (1) | EP4098594A4 (ja) |
CN (1) | CN115038422A (ja) |
CA (1) | CA3169692A1 (ja) |
WO (1) | WO2021153674A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015119055A1 (ja) * | 2014-02-06 | 2015-08-13 | 株式会社湯山製作所 | 薬品撮影装置、薬品形状測定装置、薬品払出装置 |
WO2018128133A1 (ja) | 2017-01-04 | 2018-07-12 | 株式会社トーショー | 薬剤フィーダ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103501752B (zh) * | 2011-01-20 | 2015-11-25 | 株式会社汤山制作所 | 药剂供给装置及使用药剂供给装置的药剂计数装置 |
JP5975035B2 (ja) * | 2011-09-06 | 2016-08-23 | 株式会社湯山製作所 | 薬剤カセット及び薬剤供給装置 |
US9233789B2 (en) * | 2012-03-21 | 2016-01-12 | Yuyama Mfg. Co., Ltd. | Medicine-supplying device and medicine-counting device |
TWI724134B (zh) * | 2016-03-25 | 2021-04-11 | 日商湯山製作所有限公司 | 片劑盒用轉子以及片劑盒 |
-
2021
- 2021-01-28 WO PCT/JP2021/003052 patent/WO2021153674A1/ja unknown
- 2021-01-28 CA CA3169692A patent/CA3169692A1/en active Pending
- 2021-01-28 EP EP21747412.1A patent/EP4098594A4/en active Pending
- 2021-01-28 US US17/795,695 patent/US11759396B2/en active Active
- 2021-01-28 CN CN202180011421.2A patent/CN115038422A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015119055A1 (ja) * | 2014-02-06 | 2015-08-13 | 株式会社湯山製作所 | 薬品撮影装置、薬品形状測定装置、薬品払出装置 |
WO2018128133A1 (ja) | 2017-01-04 | 2018-07-12 | 株式会社トーショー | 薬剤フィーダ |
JP2018108277A (ja) | 2017-01-04 | 2018-07-12 | 株式会社トーショー | 薬剤フィーダ |
US10828238B2 (en) | 2017-01-04 | 2020-11-10 | Tosho, Inc. | Drug feeder |
Non-Patent Citations (1)
Title |
---|
See also references of EP4098594A4 |
Also Published As
Publication number | Publication date |
---|---|
EP4098594A1 (en) | 2022-12-07 |
CN115038422A (zh) | 2022-09-09 |
EP4098594A4 (en) | 2024-01-24 |
CA3169692A1 (en) | 2021-08-05 |
US11759396B2 (en) | 2023-09-19 |
US20230056980A1 (en) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6736075B1 (ja) | 薬剤フィーダ | |
JP6736064B2 (ja) | 薬剤フィーダ | |
US10486889B2 (en) | Drug feeder | |
EP1380502B1 (en) | Tablet packing apparatus | |
JP6736074B1 (ja) | 薬剤フィーダ | |
US7861845B1 (en) | Roller sorter system | |
WO2021153674A1 (ja) | 薬剤フィーダ | |
JP7337382B2 (ja) | 薬剤フィーダ | |
JP7325756B2 (ja) | 薬剤フィーダ | |
JP2007106546A (ja) | 物品取出装置 | |
JP2022021210A (ja) | 薬剤フィーダ | |
JP7281145B2 (ja) | 薬剤フィーダ | |
JP7337383B2 (ja) | 薬剤フィーダ | |
JP7424634B2 (ja) | 薬剤フィーダ | |
JP7488568B2 (ja) | 薬剤フィーダ | |
WO2023181610A1 (ja) | 薬剤フィーダ及び錠剤分包機 | |
WO2022186348A1 (ja) | 薬剤フィーダ | |
JP4969228B2 (ja) | 個別包装薬剤自動供給装置 | |
US10329098B2 (en) | Automated vial hopper and feeder assembly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21747412 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3169692 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021214332 Country of ref document: AU Date of ref document: 20210128 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021747412 Country of ref document: EP Effective date: 20220829 |